A T L A S

Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors



VASIL TSANOV & HRISTO TSANOV

Sofia, 2023

ATLAS

Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors

Authors: Vasil Tsanov, Eng., Ph.D., Assoc. Professor & Hristo Tsanov, DM - publishers

first edition, Sofia 2023

ISBN: 978-619-91534-5-1

Genesis 1:29

"And God said, Behold, I have given you every herb bearing seed, which is upon the face of all the earth, and every tree, in the which is the fruit of a tree yielding seed; to you it shall be for meat"[i]

Let the preferred version of reading this book be electronic.
Print something really urgent on your recycled paper and printer toner!

This book is constructed in a structure aimed at limiting animal testing in laboratory and preclinical settings.

Only refurbished computers, tablets and smart devices were used in the creation of this book. Good practices have also been applied to reduce energy consumption. The goal is to prevent additional carbon load in the world around us.

Full calculations are posted here*:

Tsanov, V., Tsanov, H. (2023). Interpretable prediction for anticancer sensitivity of glycoside amides (Version 1) [Data set], Zenodo, DOI: 10.5281/zenodo.7550371

*- the information is constantly updated - choose the current version at the moment

ABSTRACT

This ATLAS presents in appended form the complete monographic study (Tsanov & Tsanov, 2023) on the subject. The idea is to bring the results out of the "heavier" didactic format required for the scientific presentation and at the same time to systematize all the information needed for the subsequent clinical research.

The present excerpt from monographic work seeks to introduce the possibility that oncological diseases become chronic (like diabetes). The theoretical basis on which we refer is the fact that cancer cells feed only on carbohydrates. In turn, there is evidence that some nitrile glycosides have anti-cancer properties.

The study is divided into four parts presented in the form of goals.

Proceeding from the particular to the general, the fine molecular structure and all possible biochemical reactions of *Amygdalin* are examined. By itself, it is highly toxic to the physiologically active animal cell. Amygdalin has NO pronounced antitumor properties. In the first goal, he examines precisely the acceptable form for admission. It is concluded that the active anticancer molecular form is a stoichiometric mixture of the amide and carboxyl derivative of the nitrile glycoside.

The second goal is to study the exact action of the anti-tumor product already introduced. After an extremely precise biochemical and mathematical analysis, a series of biochemical cycles of the exact passage of the product through the digestive system, penetration into the blood, approach to cancer cells and selective passage through their cell membrane have been deduced.

The third goal is to define the chemical and pharmaceutical molecular forms. 54 methodological and/or pharmaceutical models with hundreds of variables for each are reviewed and analyzed here.

The fourth goal (it is this purpose that is separately brought out in this edition) presents the interpretable prediction of anticancer susceptibility of glycosidic amides. The affinities of the pharmaceutical form to each known cancer cell line are reviewed. The results surpass many times all anti-cancer drugs and with significantly reduced toxicity.

In an additional part, a generalized clinical control is presented. When conducting the treatment, it is also vitally important to not divert the therapy process to irreversible pathology.

Result: The cancer can become chronic and become a practically curable disease.

ABBREVIATIONS USED IN THE TEXT

AACF	Active Anticancer Cell molecules Forms
AAF	Active apoptotic forms

CONTENT

INTRODUCTION

Assuming that some Active Anticancer Cell molecules Forms /AACF/ (secreted inside the cancer cell) could be derived from several active pharmacological forms for oral administration (in combination and/or separately) and their already considered druglikeness of the pharmaceutical form (*GPCR ligand*, *Ion channel modulator*, *Kinase inhibitor*, *Nuclear receptor ligand*, *Protease inhibitor*, *Enzyme inhibitor*, pharmacological and biological activity of oral active drugs (*Lipinski's Rule*, *Ghose Filter* and *CMC-50-Like Rule*, *Weber Filter*, *MDDR-Like Rule* and *BBB Likeness*), *QED* (*uwQED* and *wQED*), non-laboratory and no clinical information on the chemical (*Receptor activity*, *Mutagenicity*, *Carcinogenicity*, *Toxity*), *Lipophilicity*, *Water Solubility*, *Pharmacokinetics*, *Medical chemistry indicators*, etc., it is still not possible to get an idea of the influence of the studied molecules on the real cancer lines.

The main research challenge is to create a sufficiently adapted methodological scheme and at the same time to maintain the general conservatism of good oncological medical practices.

The aim of the present study is to consider the possibility of enhancing the accuracy of predicting the efficacy of the studied pharmacological oral forms using models using several different sources of information, but based on empirical studies on cancer cell lines.

- ◊ -

STRUCTURAL METHODOLOGY

Conducting the experiment

The current methodological program relies on a comparative analysis of non-identical variables. In one case it values the IC50, and in the other pharmacokinetic and druglikeness indicators of potential oral dosage forms.

In order to minimize the dualism in the interpretation, conditionally postulate some of the allowable values that would be reflected in the processing of a sample of data from the general population. They are:

a) Work is carried out with a statistical accuracy of 5% (thus aiming to equate the correlation of some of the indicators due to stereoisomerism). In cases where there is a functional dependence of values with different statistical accuracy, the one with the highest deviation is considered final;

b) To check the repeatability of the analysis (for each individual indicator), a minimum of 5 calculations are performed according to absolutely identical methodologies. If necessary, the tests are performed until a mean deviation of not more than 1.10^{-2} is obtained;

c) Some methodologies also require the definition of physical conditions; therefore, the following are accepted as inputs: temperature (T) = 310K, $pH_{oral\ cavity}$> 6.5÷7.5; $pH_{stomach}$= 0.9 ÷ 3.1. Time is not a factor - it is analyzed separately.

Input data:

Let us divide the amide/carboxylic derivatives of natural nitrile glycosides conditionally (***Tabl.1***) into 56 groups, coinciding with the active anti-cancer molecular forms (AACF).

The input data represent the molecular structural properties themselves. With the exception of 9 molecules, the test substances do not have CAS numbers (Dimitrov, et al., 2016) (Yordanova, et al., 2019). In order to achieve maximum repeatability of the results, all analyzes are performed from virtually created images.

The working file formats (§III.1, Tsanov & Tsanov, 2023) used are **.cdx* and **.c3xml*. Standard SMILE script generation followed. Each molecular record is of the "canonical SMILES" type. Some of the isomeric forms are excluded here. Therefore, for each molecule is generated, etc. "isomeric SMILES". The data from the latter will be corrective for causes in the interpretation of the results.

Table 1 *Active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane, based on hydrolyzed amide/carboxylic acid derivatives of natural nitrile glycosides*

login number		active pharmaceutical forms for oral use	active anti-cancer molecular form obtained after passage through the cell membrane
1.	A		
	B		
	C		
	D.		

	E.		
	G.		
	H.		
	I.		
2.	A		

	B		
	C		
3.			
4.	A.		
	B.		
	C.		

5.	A.		
	B.		
	C.		
	D.		
6.			
7.			

8.		
9.		
10.		
11.		
12.		
13.		
14.		

15.			
16.			
17.			
18.			
19.			
20.	A.		
	B.		

21.			
22.			
23.	A		
	B.		
24.			
25.			

26.			
27.			
28.			
29.	A.		
	B.		

	C.		
	D.		
30.			
31.	A.		
	B.		

	C.		
32.			
33.			
34.			
35.			

36.		
37.		
38.		
39.		
40.		

41.			
42.			
43.			
44.			
45.	A.		
	B.		
	C.		

	D.		
	E.		
	F.		
	G.		
	H.		
46.			

47.			
48.			
49.			
50.			
51.	A.		
	B.		

52.			
53.	A.		
	B.		
54.			
55.			
56.			



Selection of testing algorithms:

This part of the methodology is implemented through the web-based PaccMann™ (Cadow, Born, Manica, Oskooei, & Martínez, 2020) service. The training set uses data from *Genomics of Drug Sensitivity in Cancer* (Soares, et al., 2013) (GDSC) and *Cancer Cell Line Encyclopedia* (Ghandi, Huang, & Jané-Valbuena, 2019) (CCLE). The value reported here is IC50 in *log(µmol)*. The algorithm proposed by the researchers of PaccMann project gives for epistemic and aleatoric confidences (in absolute value) in the range of 0.850÷0.985. This is a good framework for bioactive substances and it is not necessary to anti-logarithm the value, but to analyze it directly within the limits: at IC50 [*log(µmol)*] <1.02 might be accepted that the studied molecule has "medicinal properties". The correction of 0.2 over the integer 1.0 comes from the statistical error of such calculations. Some of the values are negative numbers, i.e. it could be assumed that the studied molecules will also have restorative clinical properties (Sebaugh, 2011) (Gary, Zhengyin, Wensheng, & Masucci, 2012).

Applicability of results

The structure of the analysis for an interpretable prognosis of susceptibility to active anti-cancer molecular forms of transcriptome cell lines inherent in tumors considers only the described structural relationships between the molecule and the corresponding cellular effect. PaccMann outputs individual topological (and/or structural) fragments as active. The latter, in turn, can be in the amide and carboxylic oral form and in the amide and carboxylic active form. On the other hand, only a part of the molecule that is not functionally significant for the process can be described. Last but not least, it should be taken into account that the concentration of the amide pharmaceutical form is 4.87 times higher than the carboxylic form, and even after the passage of the cell membrane of the cancer cell (only the amide form) carboxylic is obtained, which maybe it with anti-cancer activity.

After several mathematical[1] and stoichiometric operations of the case, the values subjected to comparative analysis acquire the following functional dependence:

$$\boldsymbol{A_{IC50} = 4.87xAF_{IC50} + CF_{IC50} + AAF_{IC50} + 0.25xACF_{IC50}}$$

where: A_{IC50} is the IC50 activity to be analyzed; AF_{IC50} - value of the IC50 analysis for the amide pharmacological form; CF_{IC50} - value of the carboxylic pharmacological form; AAF_{IC50} - value from the IC50 analysis for the active amide form and ACF_{IC50}- value from the IC50 analysis for the active carboxylic form.

Applying the permissible values (*§III.3.4,* Tsanov & Tsanov, 2023) it follows that the maximum value for IC50 must be less than 7.35 (with statistical accuracy included).

Presentation of results

All final values are presented in tabular form, using a "heat map" - without placing the numerical values themselves. The color identification is as follows: *dark green* (#00B050) - negative values /best effect/, *light green* (#92D050) - values from 0 to 2, *dark blue* (#0070C0) - 2.01 ÷ 4.00, *light blue* (#00B0F0) - 4.01 ÷ 6.00 and *orange* (#FFC000) - 6.01 ÷ 7.35. Unstained cells do not necessarily mean that there is no activity. The values of some of them could be in a similar order to those accepted in the analysis. However, further research and individual assessments of each individual variable in the comparison process are needed.

The two different input information flows (*§III.3.4.*, Tsanov & Tsanov, 2023) and their differences in the analysis of data collection and packaging, determines the fact that some pairs of cell lines will get different results. That is why both possibilities are presented. They are interpreted together.

- ◊ -

RESULTS AND INTERPRETATION

Toxication of the cancer cell

Active apoptotic form (AAF) with manifested anticancer activity is formed according to their molecular structure. For diglycoside compounds (*Amygdalin* / *Gentiobiose* / *Lucumin* / *Primeverose* / *Vicianin* / *Vicianose*, etc.) primary enzymatic hydrolysis (*gluconases* - which are abundant in tissue fluids) of the glycosidic bonds between the individual sugars takes place. The relationship between the secondary carbohydrate and the reaction-determining group is stronger and requires a longer reaction

[1] No logarithmic conversion is performed, only the baseline numerical values of the IC50 analysis.

time and/or a specific enzyme such as *amygdalin beta-gluconase*. The latter is synthesized mainly inside the cell itself. This leads us to conclude that the passage through the cell membrane of the cancer cell (§IV.2.1-2, Tsanov & Tsanov, 2023) occurs with only one carbohydrate molecule. Once inside the cell, the only glycosidic bond is broken. This is how the **AAF**s themselves are created. Some of them are listed in ***Tabl. 2***.

Table 2 *Active apoptotic amide/carboxylic acid molecular forms, based on hydrolyzed amide/carboxylic acid derivatives of natural nitrile glycosides*

chemical formula	name	natural precursor
	(R)-2-hydroxy-2-phenylacetamide (R)-2-hydroxy-2-phenylacetic acid	Prunasin Amygdalin Lucumin Vicianin Sambunigrin
	(R)-2-hydroxy-2-(4-hydroxyphenyl)acetamide (R)-2-hydroxy-2-(4-hydroxyphenyl)acetic acid	Dhurrin Taxiphyllein Proteacin p-Glucosyloxymendelo-nitrile
	(R)-2-hydroxy-2-(3-hydroxyphenyl)acetamide (R)-2-hydroxy-2-(3-hydroxyphenyl)acetic acid	Zierin
	2-hydroxy-2-methylpropanamide 2-hydroxy-2-methylpropanoic acid	Linamarin
	(S)-2-hydroxy-2-methylbutanamide (S)-2-hydroxy-2-methylbutanoic acid	Lotaustralin
	2-hydroxy-3-methylbut-2-enamide 2-hydroxy-3-methylbut-2-enoic acid	Acacipetalin
	(2Z,4E)-4-(2-amino-1-hydroxy-2-oxoethylidene)hex-2-enedioic acid (2E,4Z)-3-(carboxymethyl)-2-hydroxyhexa-2,4-dienedioic acid	Triglochinin

	(S)-1-hydroxycyclopent-2-ene-1-carboxamide (S)-1-hydroxycyclopent-2-ene-1-carboxylic acid	Deidaclin Tetraphyllin A
	(1S,4S)-1,4-dihydroxycyclopent-2-ene-1-carboxamide (1S,4S)-1,4-dihydroxycyclopent-2-ene-1-carboxylic acid	Tetraphyllin B Volkenin Taraktophyllin
	(1R,4R)-1,4,5-trihydroxycyclopent-2-ene-1-carboxamide (1R,4R)-1,4,5-trihydroxycyclopent-2-ene-1-carboxylic acid	Gynocardin
	(Z)-2-((4S,6R)-4,6-dihydroxycyclohex-2-en-1-ylidene)acetamide (Z)-2-((4S,6R)-4,6-dihydroxycyclohex-2-en-1-ylidene)acetic acid	Menisdaurin
	(R)-2-hydroxy-3-methylbutanamide (R)-2-hydroxy-3-methylbutanoic acid	Volkenin
	(E)-2-((4S,5R,6R)-4,5,6-trihydroxycyclohex-2-en-1-ylidene)acetamide (E)-2-((4S,5R,6R)-4,5,6-trihydroxycyclohex-2-en-1-ylidene)acetic acid	Griffonin
	(Z)-2-((4R,5R,6S)-5,6-dihydroxy-4-methoxycyclohex-2-en-1-ylidene)acetamide (Z)-2-((4R,5R,6S)-5,6-dihydroxy-4-methoxycyclohex-2-en-1-ylidene)acetic acid	Bauhinin
	(E)-2-((4R,6S)-4,6-dihydroxycyclohex-2-en-1-ylidene)acetamide (E)-2-((4R,6S)-4,6-dihydroxycyclohex-2-en-1-ylidene)acetic acid	Purshianin
	(E)-2-((4S,5R,6R)-4,5,6-trihydroxycyclohex-2-en-1-ylidene)acetamide (E)-2-((4S,5R,6R)-4,5,6-trihydroxycyclohex-2-en-1-ylidene)acetic acid	Lithospermoside
	(1R,2R,4R,6S,E)-3-(2-amino-2-oxoethylidene)-2,4,6-trihydroxycyclohexyl benzoate (E)-2-((2R,3R,4S,6R)-3-(benzoyloxy)-2,4,6-trihydroxycyclohexylidene)acetic acid	Campyloside A

	(1S,2R,4R,6S,E)-3-(2-amino-2-oxoethylidene)-6-(benzoyloxy)-2,4-dihydroxycyclohexyl 1H-pyrrole-2-carboxylicate (E)-2-((2R,3S,4S,6R)-3-((1H-pyrrole-2-carbonyl)oxy)-4-(benzoyloxy)-2,6-dihydroxycyclohexylidene)acetic acid	Campyloside B
	(2S,3S)-2,3-dihydroxy-4-methoxy-1-methyl-6-oxo-1,2,3,6-tetrahydropyridine-3-carboxamide (2S,3S)-2,3-dihydroxy-4-methoxy-1-methyl-6-oxo-1,2,3,6-tetrahydropyridine-3-carboxylic acid	Acalyphin
	4-hydroxy-3-(hydroxymethyl)but-2-enamide 4-hydroxy-3-(hydroxymethyl)but-2-enoic acid	Sutherlandin
	(Z)-4-hydroxy-2-methylbut-2-enamide (Z)-4-hydroxy-2-methylbut-2-enoic acid	Rhodiocyanoside A
	(Z)-2-(hydroxymethyl)but-2-enamide (Z)-2-(hydroxymethyl)but-2-enoic acid	Rhodiocyanoside D

Each of these molecules alone would not cross the cell membrane of the cancer cell. Only those related to carbohydrate and fulfilling the conditions of (*§*IV.2.1-2, Tsanov & Tsanov, 2023) will block and/or permanently damage her normal physiology. The use of **AAF** (***Tabl. 2***) directly for treatment will lead to severe toxic and allergic responses of the body.

By themselves, these compounds or their homologues are still used in conservative chemotherapy (Chabner & Longo, 2018) (Airley, 2009) (Priestman, 2012). Glycosides such as *Rehmapicroside*, *Loganic acid*, *HMBOA D-glucoside*, *Glucose beta-1,3-isofagamine*, *Vanillyl beta-D-glucopyranoside* and others. Although they contain **AAF** of the proposed type, they would not cross the cell membrane of the cancer cell. They do not fulfill the condition of (*§IV.2.2.*, Tsanov & Tsanov, 2023), in the part of the amide derivative which is to be hydrolyzed by a transitional complex with a carboxylic acid.

The relative inertness of the glycosidic bond (*in vivo*) also allows the use of different amide-carboxylic glycosides simultaneously. This is also observed in nature with regard to the distribution of nitrile glycosides - they are often more than one representative in one plant. Thus, different AAFs can be injected simultaneously, at different concentrations and at different times, in order to closely

differentiate the different types of cancers, through the synergistic action of the controlled toxicity itself inside the "attacked" cell.

Natural nitrile glycosides would not cross the cancer cell membrane. They decompose to HCN-acid, phenyl methanol and carbohydrate. They do NOT have anticancer activity due to their inability to reach the target unchanged. These compounds, in their natural form, are extremely toxic to the human body. Their application is not a treatment, even in a higher concentration they cause irreversible pathology over the physiologically active animal cell. Dozens of their modified forms have been theoretically derived, but their amides and their carboxylic acids are the most promising for their introduction into conservative oncology. The fact is that the cancer cell itself tries to counteract it in a fairly certain way.

Determination of the drug dose

The drug dose is determined by considering all possible substances obtained by the final hydrolysis of the glycosidic bond inside the cancer cell (***Tabl. 2*** & ***3***).

Table 3 *Nature and concentration of active anticancer cell molecules obtained after crossing the cell membrane by their natural precursors*

AACF chemical formula obtained after crossing the cell membrane	**natural precursor enzymatically modified to amide and carboxylic acid**	**AACF concentration derived from 1 mg/ml pharmacological form [mg/ml]**
	Prunasin 4.87:1 Amygdalin 4.87:1 Lucumin 4.87:1 Vicianin 4.87:1 Sambunigrin 4.87:1	0.40 0.27 0.27 0.27 0.40
	Dhurrin 4.87:1 Taxiphyllin 4.87:1 Proteacin 4.87:1 p-Glucosyloxymandelonitrile 4.87:1	0.42 0.42 0.31 0.42
	Zierin 4.87:1	0.42

	Linamarin 4.87:1	0.32
	Lotaustralin 4.87:1	0.35
	Acacipetalin 4.87:1	0.34
	Triglochinin 4.87:1	0.47
	Deidaclin 4.87:1 Tetraphyllin A 4.87:1	0.36 0.36
	Tetraphyllin B 4.87:1 Volkenin 4.87:1 Taraktophyllin 4.87:1	0.39 0.39 0.39
	Gynocardin 4.87:1	0.41
	Menisdaurin 4.87:1	0.42
	Epiheterodendrin 4.87:1	0.35

	Griffonin 4.87:1	0.44
	Bauhinin 4.87:1	0.46
	Purshianin 4.87:1	0.42
	Lithospermoside 4.87:1	0.44
	Campyloside A 4.87:1	0.64
	Campyloside B 4.87:1	0.69
	Acalyphin 4.87:1	0.56
	Sutherlandin 4.87:1	0.44

	Rhodiocyanoside A 4.87:1	0.41
	Rhodiocyanoside D 4.87:1	0.41

The use of two or more pharmaceutical forms would not prevent their penetration subject to the mass ratios between the active antitumor amide and the active carboxylic transfer form.

The chemical compounds listed in ***Tabl. 2*** & ***3*** and are currently used as: anti-migrane, anti-atherosclerotic, anticoagulant, treatment of HIV, anti-cancer, anti-asthmatic, anti-hypertensive, anti-epileptic, analgesic, ocular anti-inflammatory, anti-hypertensive, hypnotic, anesthetic, anti-allergic, aromatase inhibitor, anti-ulcerative, anti-neoplastic, antibacterial, anticoccidial, contraceptive, tyrosine-kinase inhibitor treatment of mast cell tumors, etc.. The difference is that with the proposed technology they are formed inside the cell itself and thus minimize their overall toxicity in the body.

- ◊ -

FINAL REZULTS

The analysis and subsequent presentation of the results was conducted according to ***§III.3.4***, Tsanov & Tsanov, 2023:

Aerodigestive tract *(Tractus aerodigestivus)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2)*** of transcriptome cell lines inherent in tumors in the Aerodigestive tract (***Tabl.4.1. a.*** & ***b.)***, it is concluded that:

- main potential medicines: ***AACF 4.C.***, ***5.C.***, ***5.D.***, ***19.***, ***23.A.***, ***40.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.C.***, ***5.A.***, ***31.B.***, ***34.***, ***51.A.*** and ***56.A***.

Table 4.1. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Aerodigestive tract: Part 1*

cell line	active anti-cancer molecular forms																																											
	1								2			3	4							6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D																A	B			A	B					
carcinoma																																													
A-253																																													
BB30-HNC																																													
BB49-HNC																																													
BHY																																													
BICR-10																																													
BICR-22																																													
BICR-31																																													
BICR-78																																													
Ca9-22																																													
CAL-27																																													
CAL-33																																													
COLO-680N																																													
Detroit-562																																													
EC-GI-10																																													
ESO-26																																													
ESO-51																																													
FADU																																													
FLO-1																																													
H-3118																																													
HCE-4																																													
HN																																													
HO-1-N-1																																													
HO-1-u-1																																													
HSC-2																																													
HSC-3																																													
HSC-4																																													
JHU-011																																													
JHU-022																																													
JHU-029																																													
KON																																													
KOSC-2																																													


KYAE-1
KYSE-140
KYSE-150
KYSE-180
KYSE-220
KYSE-270
KYSE-410
KYSE-450
KYSE-50
KYSE-510
KYSE-520
KYSE-70
LB771-HNC
OACM5-1
OACp-4C
OE-19
OE-21
OSC-19
OSC-20
PCI-15A
PCI-30
PCI-38
PCI-4B
PCI-6A
PE/CA-PJ15
RPMI-2650
SAS
SAT
SCC-15
SCC-25
SCC-4
SCC-9
SCC-90
SK-GT-4
SKN-3
TE-1
TE-10
TE-11
TE-12
TE-15
TE-4
TE-5
TE-6
TE-8
TE-9
T-T
other
DOK
OE-33
color scale of activity - in the direction of decrease:

Table 4.1. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Aerodigestive tract: Part 2*





Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Autonomic ganglion *(Ganglion autonomicum)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Autonomic ganglion (***Tabl.4.2. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 1.A.***, ***1.B.***, ***1.C.***, ***4.***, ***7.***, ***9.***, ***12.***, ***14.*** and ***19.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 2.A.***, ***5.***, ***6.***, ***8.***, ***10.***, ***11.*** and ***22***.

Table 4.2. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Autonomic ganglion: Part 1*



Table 4.2. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Autonomic ganglion: Part 2*



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Biliary tract *(Ductus biliaris)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Biliary tract (***Tabl.4.3. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 5.A.***, ***5.C.***, ***12.***, ***19.***, ***23.A.***, ***34.***, ***40.***, ***51.A.***, ***56.A.*** *and* ***56.B***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.C.***, ***1.D.***, ***4.A.***, ***4.B.***, ***4.C.***, ***5.B.***, ***5.D.***, ***30.***, ***31.A.***, ***31.B.***, ***32.***, ***36.***, ***42.***, ***44.***, ***45.B.***, ***48.***, ***49.***, ***52.*** and **55**.

Table 4.3. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Biliary tract: Part 1*



Table 4.3. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Biliary tract: Part 2*



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Bone *(Anatomia ossis)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Bone (***Tabl.4.4. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 4.C.***, ***5.C.***, ***5.D.***, ***40.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 23.A.*** and ***31.B***.

Table 4.4. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Bone: Part 1*

cell line	active anti-cancer molecular forms																																															
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	G	H	I	A	B	C		A	B	C	A	B	C	D																A	B			A	B						
chondrosarcoma																																															
CAL-78																																															
CAL-78*																																															
CHSA-0011																																															
CHSA-0108																																															
CHSA-8926																																															
H-EMC-SS																																															
Ewings sarcoma-peripheral primitive neuroectodermal tumour																																															
A-673																																															
CADO-ES1																																															
CADO-ES1*																																															
ES-1																																															
ES-3																																															
ES-4																																															
ES-5																																															
ES-6																																															
ES-7																																															
ES-8																																															
EW-1																																															
EW-11																																															
EW-12																																															
EW-13																																															
EW-16																																															
EW-18																																															
EW-22																																															
EW-24																																															
EW-3																																															
EW-7																																															
SK-ES-1																																															


SK-ES-1*
SK-PN-DW
TC-71
TC-71*
osteosarcoma
CAL-72
G-292, clone A141B1
G-292, clone A141B1*
HOS
HOS*
HuO-3N1
HuO-9
MG-63
MG-63*
NOS-1
NY
Saos-2
Saos-2*
U-2-OS
other
143B
CS-1
EW-8
EWS-502
HS-706.T
HS-737.T
HS-819.T
HS-821.T
HS-822.T
HS-863.T
HS-870.T
HS-888.T
MHH-ES-1
OUMS-27
RD-ES
SJSA-1
SJSA-1*
SK-N-MC
SW-1353
T-173
TC-32
U-2-OS
color scale of activity - in the direction of decrease:

Table 4.4. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Bone: Part 2*





Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Breast *(Mamma)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Breast (***Tabl.4.5. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 4.C.***, ***5.C.***, ***5.D.***, ***19.***, ***23.A.***, ***31.B.***, ***40.***, ***48.***, ***51.A.***, ***56.A.***, and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 5.A.***, ***34.***, ***39.***, ***45.D.***, ***45.*** and ***51.B***.

***Table 4.5. a** Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Breast: Part 1*

cell line	active anti-cancer molecular forms																																											
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D															A	B			A	B					
carcinoma																																												
AU-565																																												
AU-565*																																												
BT-20																																												
BT-20*																																												
BT-474																																												
BT-474*																																												
BT-483																																												
BT-483*																																												
BT-549																																												
BT-549*																																												
CAL-120																																												
CAL-120*																																												
CAL-148																																												
CAL-148*																																												
CAL-51																																												
CAL-51*																																												
CAL-851																																												
CAL-851*																																												
CAMA-1																																												
CAMA-1*																																												
COLO-824																																												
COLO-824*																																												
DU-4475																																												
EFM-19																																												
EFM-19*																																												
EFM-192A																																												
EFM-192A*																																												
EVSA-T																																												
EVSA-T*																																												
HCC-1143																																												
HCC-1143*																																												
HCC-1187																																												
HCC-1187*																																												
HCC-1395																																												
HCC-1395*																																												
HCC-1419																																												
HCC-1419*																																												
HCC-1428																																												
HCC-1428*																																												
HCC-1500																																												
HCC-1500*																																												
HCC-1569																																												
HCC-1569*																																												


HCC-1599
HCC-1599*
HCC-1806
HCC-1806*
HCC-1937
HCC-1937*
HCC-1954
HCC-1954*
HCC-202
HCC-202*
HCC-2157
HCC-2157*
HCC-2218
HCC-2218*
HCC-38
HCC-38*
HCC-70
HCC-70*
HDQ-P1
HDQ-P1*
Hs-578T
Hs-578T*
JIMT-1
JIMT-1*
MCF-7
MCF-7*
MDA-MB-157
MDA-MB-157*
MDA-MB-231
MDA-MB-231*
MDA-MB-330
MDA-MB-361
MDA-MB-361*
MDA-MB-415
MDA-MB-415*
MDA-MB-436
MDA-MB-436*
MDA-MB-453
MDA-MB-453*
MDA-MB-468
MDA-MB-468*
MFM-223
MRK-nu-1
OCUB-M
T-47D
T-47D*
UACC-812
UACC-812*
UACC-893
UACC-893*

ZR-75-30																																											
ZR-75-30*																																											
other																																											
HMC-1-8																																											
HMEL																																											
HS-274.T																																											
HS-281.T																																											
HS-343.T																																											
HS-606.T																																											
HS-739.T																																											
HS-742.T																																											
KPL-1																																											
MDA-MB-134-VI																																											
MDA-MB-175-VII																																											
SK-BR-3																																											
YMB-1																																											
ZR-75-1																																											

color scale of activity - in the direction of decrease:

***Table 4.5. b** Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Breast: Part 2*

cell line	active anti-cancer molecular forms																																										
	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45								46	47	48	49	50	51		52	53		54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H						A	B		A	B			A	B
carcinoma																																											
AU-565																																											
AU-565*																																											
BT-20																																											
BT-20*																																											
BT-474																																											
BT-474*																																											
BT-483																																											
BT-483*																																											
BT-549																																											
BT-549*																																											
CAL-120																																											
CAL-120*																																											
CAL-148																																											
CAL-148*																																											
CAL-51																																											
CAL-51*																																											
CAL-851																																											
CAL-851*																																											
CAMA-1																																											
CAMA-1*																																											
COLO-824																																											


COLO-824*
DU-4475
EFM-19
EFM-19*
EFM-192A
EFM-192A*
EVSA-T
EVSA-T*
HCC-1143
HCC-1143*
HCC-1187
HCC-1187*
HCC-1395
HCC-1395*
HCC-1419
HCC-1419*
HCC-1428
HCC-1428*
HCC-1500
HCC-1500*
HCC-1569
HCC-1569*
HCC-1599
HCC-1599*
HCC-1806
HCC-1806*
HCC-1937
HCC-1937*
HCC-1954
HCC-1954*
HCC-202
HCC-202*
HCC-2157
HCC-2157*
HCC-2218
HCC-2218*
HCC-38
HCC-38*
HCC-70
HCC-70*
HDQ-P1
HDQ-P1*
Hs-578T
Hs-578T*
JIMT-1
JIMT-1*
MCF-7
MCF-7*
MDA-MB-157
MDA-MB-157*



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Central nervous system *(Systema nervosum centrale)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Central nervous system (***Tabl.4.6. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 1.C.***, ***4.C.***, ***5.A.***, ***5.C.***, ***5.D.***, ***19.***, ***23.A.***, ***30.***, ***31.B.***, ***34.***, ***39.***, ***40.***, ***45.D.***, ***51.A.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.D.***, ***12.***, ***25.***, ***31.A.***, ***33.***, ***37.***, ***43.***, ***44.***, ***45.A.***, ***45.H.***, ***46.***, ***48.*** *and* ***49***.

Table 4.6. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Central nervous system: Part 1*

cell line	active anti-cancer molecular forms																																												
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	D	H	A	B	C		A	B	C	A	B	C	D																			A	B							
glioma																																														
A-172																																														
GaMG																																														
H-4																																														
SF-126																																														
SF-295																																														
SW-1088																																														
SW-1783																																														
T-98G																																														
other																																														
1321-N1																																														
42-MG-BA																																														
8-MG-BA																																														
A-1207																																														
AM-38																																														
BECKER																																														
CAS-1																																														
CCF-STTG1																																														
CH-157MN																																														
D-283Med																																														
D-341Med																																														
Daoy																																														
DBTRG-05MG																																														
DK-MG																																														
F-5																																														
GB-1																																														
GI-1																																														
GMS-10																																														
GOS-3																																														
HS-683																																														


IOMM-Lee
KALS-1
KG-1-C
KNS-42
KNS-60
KNS-81
KS-1
LN-18
LN-215
LN-229
LN-235
LN-319
LN-340
LN-382
LN-428
LN-443
LN-464
LN-Z308
M-059-K
MOG-G-CCM
MOG-G-UVW
NMC-G1
ONS-76
SF-172
SF-767
SNB-19
SNU-1105
SNU-201
SNU-466
SNU-489
SNU-626
SNU-738
TM-31
U-118-MG
U-138-MG
U-178
U-251-MG
U-343
U-87-MG
YH-13
YKG-1
color scale of activity - in the direction of decrease:

Table 4.6. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Central nervous system: Part 2*





Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Digestive system *(Apparatus digestorius)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Digestive system (***Tabl.4.7. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 4.C.***, ***5.C.***, ***40.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 5.D.*** and ***23.A***.

Table 4.7. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Digestive system: Part 1*



SNU-449																																											
SNU-475																																											
TGBC-11TKB																																											
TGBC-1TKB																																											
TGBC-24TKB																																											
other																																											
Hep 3B2 1-7																																											
JHH-2																																											
JHH-4																																											
SCH																																											

color scale of activity - in the direction of decrease:

Table 4.7. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Digestive system: Part 2*

cell line	active anti-cancer molecular forms																																										
	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45								46	47	48	49	50	51		52	53		54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H						A	B		A	B			A	B
carcinoma																																											
23132-87																																											
AGS																																											
C-3A																																											
ECC-10																																											
ECC-12																																											
EGI-1																																											
ETK-1																																											
FU-97																																											
GCIY																																											
GT-3TKB																																											
HGC-27																																											
HLE																																											
Hs-746T																																											
HSC-39																																											
HuCCT-1																																											
HuH-1																																											
HuH-7																																											
HuTu-80																																											
IM-95																																											
JHH-1																																											
JHH-6																																											
JHH-7																																											
KATO-III																																											
MK-N1																																											
MK-N28																																											
MK-N45																																											
MK-N7																																											
NCI-N87																																											



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Endometrium *(Endometrium)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Endometrium (***Tabl.4.8. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 1.C.***, ***4.C.***, ***5.A.***, ***5.C.***, ***5.D.***, ***19.***, ***23.A.***, ***30.***, ***31.B.***, ***31.C.***, ***34.***, ***36.***, ***39.***, ***40.***, ***44.***, ***45.B.***, ***45.E.***, ***46.***, ***48.***, ***49.***, ***51.A.***, ***51.B.***, ***52.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.D.***, ***4.A.***, ***4.B.***, ***5.B.***, ***7.***, ***12.***, ***25.***, ***31.A.***, ***32.***, ***33.***, ***37.***, ***38.***, ***47.*** and ***55***.

Table 4.8. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Endometrium: Part 1*



Table 4.8. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Endometrium: Part 2*



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Hematopoietic and lymphoid tissues *(Haematopoeticarum lymphoidearumque)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Hematopoietic and lymphoid tissues (***Tabl.4.9. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 1.C.***, ***4.C.***, ***5.A.***, ***5.B.***, ***5.C.***, ***5.D.***, ***7.***, ***12.***, ***19.***, ***23.A.***, ***25.***, ***30.***, ***31.A.***, ***31.B.***, ***31.C.***, ***33.***, ***34.***, ***35.***, ***37.***, ***38.***, ***39.***, ***40.***, ***41.***, ***42.***, ***43.***, ***44.***, ***45.B.***, ***45.E.***, ***46.***, ***47.***, ***48.***, ***49.***, ***50.***, ***52.A.***, ***51.B.***, ***52.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.D.***, ***4.A.***, ***4.B.***, ***9.***, ***11.***, ***14.***, ***32.***, ***45.H.*** and ***55***.

Table 4.9. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Hematopoietic and lymphoid tissues: Part 1*




BL-41
BL-70
BV-173
CI-1
CMK-11-5
CMK-86
CML-T1
COLO-677
COLO-775
Daudi
DND-41
DoHH-2
EB-1
EM-2
EoL-1
F-36P
GA-10
GDM-1
Granta-519
HDLM-2
HD-MY-Z
HEL-92.1.7
HL-60
HPB-ALL
HS-604.T
HS-611.T
HS-616.T
HS-751.T
HT
HTK
HuNS-1
HuT-102
HuT-78
JeKo-1
JJN-3
JK-1
Jurkat
JURL-MK1
JVM-2
JVM-3
K-562
KARPAS-299
KARPAS-422
KARPAS-620
Kasumi-1
Kasumi-2
Kasumi-6
KCL-22
KE-37
KE-97


KG-1
KHM-1B
Ki-JK
KMH-2
KMM-1
KMS-11
KMS-12-BM
KMS-18
KMS-20
KMS-21-BM
KMS-26
KMS-27
KMS-28-BM
KMS-34
KO-52
KOPN-8
KYO-1
L-1236
L-363
L-428
L-540
LAMA-84
LP-1
M-07e
ME-1
MEC-1
MEC-2
MEG-01
MHH-CALL-2
MHH-CALL-3
MHH-CALL-4
Mino
MJ
MOLM-13
MOLM-16
MOLM-6
MOLP-2
MOLP-8
MOLT-13
MOLT-16
MOLT-4
MONO-MAC-1
MONO-MAC-6
MOTN-1
MUTZ-5
MV-4-11
NALM-1
NALM-19
NALM-6
NB-4
NCIH-929


NCO-2
NOMO-1
NU-DHL-1
NU-DUL-1
OCI-AML-2
OCI-AML-3
OCI-AML-5
OCI-Ly-10
OCI-Ly-19
OCI-Ly-3
OCI-M1
OPM-2
P12-ICHIKAWA
P31/FUJ
P3HR-1
PCM-6
Peer
PF-382
Pfeiffer
PL-21
Raji
RCH-ACV
REC-1
Ri-1
RPMI-8226
RPMI-8402
RS4;11
SEM
SET-2
SIG-M5
SKM-1
SK-MM-2
SR-786
SU-DHL-1
SU-DHL-10
SU-DHL-4
SU-DHL-5
SU-DHL-6
SU-DHL-8
SUP-B15
SUP-HD1
SUP-M2
SUP-T1
SUP-T11
TALL-1
TF-1
THP-1
TO-175.T
Toledo
U-266-B1



Table 4.9. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Hematopoietic and lymphoid tissues: Part 2*




BV-173
CI-1
CMK-11-5
CMK-86
CML-T1
COLO-677
COLO-775
Daudi
DND-41
DoHH-2
EB-1
EM-2
EoL-1
F-36P
GA-10
GDM-1
Granta-519
HDLM-2
HD-MY-Z
HEL-92.1.7
HL-60
HPB-ALL
HS-604.T
HS-611.T
HS-616.T
HS-751.T
HT
HTK
HuNS-1
HuT-102
HuT-78
JeKo-1
JJN-3
JK-1
Jurkat
JURL-MK1
JVM-2
JVM-3
K-562
KARPAS-299
KARPAS-422
KARPAS-620
Kasumi-1
Kasumi-2
Kasumi-6
KCL-22
KE-37
KE-97
KG-1
KHM-1B


Ki-JK
KMH-2
KMM-1
KMS-11
KMS-12-BM
KMS-18
KMS-20
KMS-21-BM
KMS-26
KMS-27
KMS-28-BM
KMS-34
KO-52
KOPN-8
KYO-1
L-1236
L-363
L-428
L-540
LAMA-84
LP-1
M-07e
ME-1
MEC-1
MEC-2
MEG-01
MHH-CALL-2
MHH-CALL-3
MHH-CALL-4
Mino
MJ
MOLM-13
MOLM-16
MOLM-6
MOLP-2
MOLP-8
MOLT-13
MOLT-16
MOLT-4
MONO-MAC-1
MONO-MAC-6
MOTN-1
MUTZ-5
MV-4-11
NALM-1
NALM-19
NALM-6
NB-4
NCIH-929
NCO-2
NOMO-1


NU-DHL-1
NU-DUL-1
OCI-AML-2
OCI-AML-3
OCI-AML-5
OCI-Ly-10
OCI-Ly-19
OCI-Ly-3
OCI-M1
OPM-2
P12-ICHIKAWA
P31/FUJ
P3HR-1
PCM-6
Peer
PF-382
Pfeiffer
PL-21
Raji
RCH-ACV
REC-1
Ri-1
RPMI-8226
RPMI-8402
RS4;11
SEM
SET-2
SIG-M5
SKM-1
SK-MM-2
SR-786
SU-DHL-1
SU-DHL-10
SU-DHL-4
SU-DHL-5
SU-DHL-6
SU-DHL-8
SUP-B15
SUP-HD1
SUP-M2
SUP-T1
SUP-T11
TALL-1
TF-1
THP-1
TO-175.T
Toledo
U-266-B1
U-937
UT-7

Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Kidney *(Ren)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Kidney (***Tabl.4.10. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 4.C.***, ***5.C.***, ***40.***, ***51.A.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 19.***, ***23.***, ***31.B.*** and ***45.E***.

Table 4.10. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Kidney: Part 1*

cell line	active anti-cancer molecular forms																																											
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D															A	B			A	B							
adrenal cortical carcinoma																																													
SW-13																																													
carcinoma																																													
769-P																																													
769-P*																																													
786-O																																													
786-O*																																													
A-498																																													
A-498*																																													
A-704																																													
A-704*																																													
ACHN																																													
ACHN*																																													
BB65-RCC																																													
BFTC-909																																													
BFTC-909*																																													
Caki-1																																													
Caki-1*																																													
CAL-54																																													
HA7-RCC																																													


KMRC-1
KMRC-1*
KMRC-20
KMRC-20*
LB1047-RCC
LB2241-RCC
LB996-RCC
NCC010
NCC021
OS-RC-2
OS-RC-2*
RCC-10RGB
RCC-10RGB*
RCC-AB
RCC-ER
RCC-FG2
RCC-JF
RCC-JW
RCC-MF
RXF-393
SN-12C
TK-10
UO-31
VMRC-RCZ
VMRC-RCZ*
rhabdoid tumour
G-401
other
Caki-2
CAL-54
HEK-TE
HK-2
KMRC-2
KMRC-3
RCC-4
SK-RC-20
SK-RC-31
SLR-20
SLR-21
SLR-23
SLR-24
SLR-25
SLR-26
SNU-1272
SNU-349
SW-156
TUHR-10TKB
TUHR-14TKB
TUHR-4TKB
UM-RC-2

UM-RC-6																																											
UOK-101																																											
VMRC-RCW																																											

color scale of activity - in the direction of decrease:

***Table 4.10. b** Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Kidney: Part 2*

cell line	active anti-cancer molecular forms																																									
	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45								46	47	48	49	50	51		52	53		54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H						A	B		A	B			A	B
adrenal cortical carcinoma																																											
SW-13																																											
carcinoma																																											
769-P																																											
769-P*																																											
786-O																																											
786-O*																																											
A-498																																											
A-498*																																											
A-704																																											
A-704*																																											
ACHN																																											
ACHN*																																											
BB65-RCC																																											
BFTC-909																																											
BFTC-909*																																											
Caki-1																																											
Caki-1*																																											
CAL-54																																											
HA7-RCC																																											
KMRC-1																																											
KMRC-1*																																											
KMRC-20																																											
KMRC-20*																																											
LB1047-RCC																																											
LB2241-RCC																																											
LB996-RCC																																											
NCC010																																											
NCC021																																											
OS-RC-2																																											
OS-RC-2*																																											
RCC-10RGB																																											
RCC-10RGB*																																											
RCC-AB																																											



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Large intestine *(Intestinum crassum)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Large intestine (***Tabl.4.11. a*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 4.C.***, ***5.A.***, ***5.C.***, ***5.D.***, ***19.***, ***23.A.***, ***31.B.***, ***34.***, ***40.***, ***51.A.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and/or substitution on medical grounds: ***AACF 1.C.***, ***31.C.***, ***39.***, ***45.E.*** and ***48***.

Table 4.11. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Large intestine: Part 1*

cell line	active anti-cancer molecular forms																																											
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D															A	B			A	B					
	carcinoma																																											
C2BBe1																																												
C2BBe1*																																												
CaR-1																																												
CCK-81																																												
CCK-81*																																												
CL-11																																												
CL-11*																																												
CL-34																																												
CL-34*																																												
CL-40																																												
CL-40*																																												
COLO-205																																												
COLO-205*																																												
COLO-320HSR																																												
COLO-678																																												
COLO-678*																																												
CW-2																																												
CW-2*																																												
GP5d																																												
HCC-2998																																												
HCC-56																																												
HCC-56*																																												
HCT-116																																												
HCT-116*																																												
HCT-15																																												
HCT-15*																																												
HT-115																																												
HT-115*																																												
HT-29																																												
HT-29*																																												
HT-55																																												


HT-55*
KM-12
KM-12*
LoVo
LoVo*
LS-1034
LS-1034*
LS-123
LS-123*
LS-180
LS-180*
LS-411N
LS-411N*
LS-513
LS-513*
MDST-8
MDST-8*
NCI-H630
NCI-H716
NCI-H716*
NCI-H747
NCI-H747*
RCM-1
RCM-1*
RKO
RKO*
SK-CO-1
SK-CO-1*
SNU-1040
SNU-1040*
SNU-175
SNU-175*
SNU-407
SNU-407*
SNU-61
SNU-61*
SNU-81
SNU-81*
SNU-C1
SNU-C1*
SNU-C2B
SNU-C5
SNU-C5*
SW-1116
SW-1116*
SW-1417
SW-1417*
SW-1463
SW-1463*
SW-48

SW-48*																																											
SW-620																																											
SW-620*																																											
SW-837																																											
SW-837*																																											
SW-948																																											
SW-948*																																											
T-84																																											
T-84*																																											
other																																											
CL-14																																											
COLO-201																																											
COLO-320																																											
DLD-1																																											
GP2d																																											
HCT-8																																											
Hs-255.T																																											
Hs-675.T																																											
Hs-698.T																																											
NCI-H508																																											
OUMS-23																																											
SNU-1033																																											
SNU-1197																																											
SNU-283																																											
SNU-503																																											
SNU-C2A																																											
SNU-C4																																											
SW-403																																											
SW-480																																											

color scale of activity - in the direction of decrease:

Table 4.11. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Large intestine: Part 2*

cell line	active anti-cancer molecular forms																																										
	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45								46	47	48	49	50	51		52	53		54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H						A	B		A	B			A	B
carcinoma																																											
C2BBe1																																											
C2BBe1*																																											
CaR-1																																											
CCK-81																																											
CCK-81*																																											
CL-11																																											
CL-11*																																											


CL-34
CL-34*
CL-40
CL-40*
COLO-205
COLO-205*
COLO-320HSR
COLO-678
COLO-678*
CW-2
CW-2*
GP5d
HCC-2998
HCC-56
HCC-56*
HCT-116
HCT-116*
HCT-15
HCT-15*
HT-115
HT-115*
HT-29
HT-29*
HT-55
HT-55*
KM-12
KM-12*
LoVo
LoVo*
LS-1034
LS-1034*
LS-123
LS-123*
LS-180
LS-180*
LS-411N
LS-411N*
LS-513
LS-513*
MDST-8
MDST-8*
NCI-H630
NCI-H716
NCI-H716*
NCI-H747
NCI-H747*
RCM-1
RCM-1*
RKO
RKO*


SK-CO-1
SK-CO-1*
SNU-1040
SNU-1040*
SNU-175
SNU-175*
SNU-407
SNU-407*
SNU-61
SNU-61*
SNU-81
SNU-81*
SNU-C1
SNU-C1*
SNU-C2B
SNU-C5
SNU-C5*
SW-1116
SW-1116*
SW-1417
SW-1417*
SW-1463
SW-1463*
SW-48
SW-48*
SW-620
SW-620*
SW-837
SW-837*
SW-948
SW-948*
T-84
T-84*
other
CL-14
COLO-201
COLO-320
DLD-1
GP2d
HCT-8
Hs-255.T
Hs-675.T
Hs-698.T
NCI-H508
OUMS-23
SNU-1033
SNU-1197
SNU-283
SNU-503
SNU-C2A
SNU-C4

Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Leukemia *(Leuchaemia)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Leukemia (***Tabl.4.12. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 1.C.***, ***4.C.***, ***5.C.***, ***5.D.***, ***19.***, ***25.***, ***30.***, ***31.B.***, ***31.C.***, ***34.***, ***39.***, ***40.***, ***45.E.***, ***50.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.D.***, ***4.A.***, ***4.B.***, ***5.A.***, ***5.B.***, ***7.***, ***12.***, ***32.***, ***33.***, ***42.***, ***43.***, ***44.***, ***45.B.***, ***49.***, ***50.***, ***51.A.*** and ***51.B***.

Table 4.12. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Leukemia: Part 1*

cell line	active anti-cancer molecular forms																																											
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D																A	B			A	B							
	haematopoietic neoplasm																																												
BV-173																																													
CESS																																													
CMK																																													
CML-T1																																													
EM-2																																													
EoL-1																																													
GDM-1																																													
HEL																																													
HL-60																																													
JURL-MK1																																													
K-562																																													
Kasumi-1																																													
KCL-22																																													
KG-1																																													
KMOE-2																																													
KU-812																																													
KY-821																																													
LAMA-84																																													


ME-1
MEG-01
ML-2
MOLM-13
MOLM-16
MONO-MAC-6
MV-4-11
NB-4
NKM-1
NOMO-1
OCI-AML-2
OCI-AML-3
OCI-AML-5
OCI-M1
P31/FUJ
PL-21
QIMR-WIL
RPMI-8866
RS4;11
SIG-M5
SKM-1
THP-1
lymphoid neoplasm
697
ALL-PO
ALL-SIL
ATN-1
BALL-1
BE-13
CCRF-CEM
CTV-1
DND-41
GR-ST
HAL-01
HC-1
HH
Jurkat
Karpas-231
Karpas-45
KE-37
KOPN-8
LC4-1
Loucy
MHH-CALL-2
MHH-PREB-1
MLMA
MN-60
MOLT-13
MOLT-16
MOLT-4
Mo-T



Table 4.12. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Leukemia: Part 2*

cell line \ active anti-cancer molecular forms	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45								46	47	48	49	50	50	51		52	53	54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H							A	B					A	B
haematopoietic neoplasm																																											
BV-173																																										
CESS																																										
CMK																																										
CML-T1																																										
EM-2																																										
EoL-1																																										
GDM-1																																										
HEL																																										
HL-60																																										
JURL-MK1																																										
K-562																																										
Kasumi-1																																										
KCL-22																																										
KG-1																																										
KMOE-2																																										
KU-812																																										
KY-821																																										
LAMA-84																																										
ME-1																																										
MEG-01																																										
ML-2																																										
MOLM-13																																										
MOLM-16																																										
MONO-MAC-6																																										
MV-4-11																																										


NB-4
NKM-1
NOMO-1
OCI-AML-2
OCI-AML-3
OCI-AML-5
OCI-M1
P31/FUJ
PL-21
QIMR-WIL
RPMI-8866
RS4;11
SIG-M5
SKM-1
THP-1
lymphoid neoplasm
697
ALL-PO
ALL-SIL
ATN-1
BALL-1
BE-13
CCRF-CEM
CTV-1
DND-41
GR-ST
HAL-01
HC-1
HH
Jurkat
Karpas-231
Karpas-45
KE-37
KOPN-8
LC4-1
Loucy
MHH-CALL-2
MHH-PREB-1
MLMA
MN-60
MOLT-13
MOLT-16
MOLT-4
Mo-T
NALM-6
P12-Ichikawa
P30/OHK
PF-382
RCH-ACV
Reh
ROS-50



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Liver *(Hepar)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Liver (***Tabl.4.13. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 1.C.***, ***4.C.***, ***5.A.***, ***5.C.***, ***5.D.***, ***19.***, ***31.B.***, ***34.***, ***40.***, ***45.E.***, ***51.A.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 4.A.***, ***12.***, ***31.A.***, ***42.***, ***43.***, ***44.***, ***45.B.***, ***46.***, ***48.*** and ***51.B.***

Table 4.13. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Liver: Part 1*

cell line \ active anti-cancer molecular forms	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D															A	B			A	B						
carcinoma																																												
Hep-G2/C3A																																												
HLE																																												
other																																											
PLC/PRF/5																																												
Hep-3B2.1-7																																												
Hep-G2																																												
HLF																																												
HuH-1																																												
HuH-6																																												
HuH-7																																												
JHH-1																																												
JHH-2																																												
JHH-4																																												
JHH-5																																												
JHH-6																																												
JHH-7																																												

Li-7																																											
NCI-H684																																											
PLC/PRF/5																																											
SK-HEP-1																																											
SNU-182																																											
SNU-387																																											
SNU-398																																											
SNU-423																																											
SNU-449																																											
SNU-475																																											
SNU-761																																											
SNU-878																																											
SNU-886																																											

color scale of activity - in the direction of decrease:

***Table 4.13. b** Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Liver: Part 2*

cell line	active anti-cancer molecular forms																																										
	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45								46	47	48	49	50	51		52	53		54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H						A	B		A	B			A	B
carcinoma																																											
Hep-G2/C3A																																											
HLE																																											
other																																											
PLC/PRF/5																																											
Hep-3B2.1-7																																											
Hep-G2																																											
HLF																																											
HuH-1																																											
HuH-6																																											
HuH-7																																											
JHH-1																																											
JHH-2																																											
JHH-4																																											
JHH-5																																											
JHH-6																																											
JHH-7																																											
Li-7																																											
NCI-H684																																											
PLC/PRF/5																																											
SK-HEP-1																																											
SNU-182																																											
SNU-387																																											
SNU-398																																											



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Lung *(Pulmo)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Lung (***Tabl.4.14. a*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 4.C.***, ***5.C.***, ***5.D.***, ***19.***, ***23.A.***, ***31.B.***, ***40.***, ***51.A.***, ***56.A.*** and ***56.B.;***
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.C.***, ***5.A.***, ***12.***, ***31.C.***, ***34.***, ***39.***, ***45.E.*** and ***48***.

Table 4.14. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Lung: Part 1*

cell line	active anti-cancer molecular forms																																											
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D															A	B			A	B						
carcinoid-endocrine_tumour																																												
NCI-H835																																													
UMC-11																																													
carcinoma																																												
201T																																													
A-427																																													
A-549																																													
A-549*																																													
ABC-1																																													
ABC-1*																																													
BEN																																													
BEN*																																													
CAL-12T																																													
CAL-12T*																																													
CAL-U3																																													
CAL-U3*																																													


CAL-U6
CAL-U6*
ChaGo-K-1
ChaGo-K-1*
COLO-668
COLO-668*
COR-L105
COR-L105*
COR-L23
COR-L23*
COR-L279
COR-L279*
COR-L303
COR-L311
COR-L311*
COR-L32
COR-L88
COR-L88*
COR-L95
COR-L95*
CPC-N
CPC-N*
DMS-114
DMS-114*
DMS-273
DMS-273*
DMS-53
DMS-53*
DMS-79
DMS-79*
EBC-1
EBC-1*
EKVX
EMC-BAC-1
EMC-BAC-2
EPLC-272H
EPLC-272H*
NCI-H3255
HARA
HARA*
HCC-15
HCC-15*
HCC-366
HCC-366*
HCC-44
HCC-44*
HCC-78
HCC-78*
HCC-827
HCC-827*
HOP-62


HOP-92
IA-LM
IA-LM*
IST-SL1
IST-SL2
KNS-62
KNS-62*
LB647-SCLC
LC-1/sq-SF
LC-1/sq-SF*
LC-2/ad
LCLC-103H
LCLC-103H*
LCLC-97TM1
LCLC-97TM1*
LK-2
LK-2*
LOU-NH91
LOU-NH91*
Lu-134A
Lu-135
Lu-139
Lu-165
Lu-65
Lu-65*
Lu-99A
LXF-289
LXF-289*
MS-1
NCI-H1048
NCI-H1048*
NCI-H1092
NCI-H1092*
NCI-H1105
NCI-H1105*
NCI-H1155
NCI-H1155*
NCI-H1299
NCI-H1299*
NCI-H1304
NCI-H1341
NCI-H1341*
NCI-H1355
NCI-H1355*
NCI-H1395
NCI-H1395*
NCI-H1417
NCI-H1435
NCI-H1435*
NCI-H1436


NCI-H1436*
NCI-H146
NCI-H146*
NCI-H1563
NCI-H1563*
NCI-H1568
NCI-H1568*
NCI-H1573
NCI-H1573*
NCI-H1581
NCI-H1581*
NCI-H1623
NCI-H1623*
NCI-H1648
NCI-H1648*
NCI-H1650
NCI-H1650*
NCI-H1651
NCI-H1651*
NCI-H1666
NCI-H1666*
NCI-H1688
NCI-H1693
NCI-H1693*
NCI-H1694
NCI-H1694*
NCI-H1703
NCI-H1703*
NCI-H1734
NCI-H1734*
NCI-H1755
NCI-H1755*
NCI-H1770
NCI-H1781
NCI-H1781*
NCI-H1792
NCI-H1792*
NCI-H1793
NCI-H1793*
NCI-H1836
NCI-H1836*
NCI-H1838
NCI-H1838*
NCI-H1869
NCI-H1869*
NCI-H187
NCI-H1876
NCI-H1876*
NCI-H1915
NCI-H1915*
NCI-H1944


NCI-H1944*
NCI-H196
NCI-H196*
NCI-H1963
NCI-H1963*
NCI-H1975
NCI-H1975*
NCI-H1993
NCI-H2009
NCI-H2009*
NCI-H2023
NCI-H2023*
NCI-H2029
NCI-H2029*
NCI-H2030
NCI-H2030*
NCI-H2066
NCI-H2066*
NCI-H2085
NCI-H2085*
NCI-H2087
NCI-H2087*
NCI-H209
NCI-H209*
NCI-H211
NCI-H211*
NCI-H2110
NCI-H2110*
NCI-H2122
NCI-H2122*
NCI-H2135
NCI-H2141
NCI-H2141*
NCI-H2170
NCI-H2170*
NCI-H2172
NCI-H2172*
NCI-H2196
NCI-H2196*
NCI-H2227
NCI-H2227*
NCI-H2228
NCI-H2228*
NCI-H226
NCI-H226*
NCI-H2291
NCI-H2291*
NCI-H23
NCI-H23*
NCI-H2342


NCI-H2342*
NCI-H2347
NCI-H2347*
NCI-H2405
NCI-H2405*
NCI-H2444
NCI-H2444*
NCI-H250
NCI-H292
NCI-H3122
NCI-H322*
NCI-H322M
NCI-H345
NCI-H358
NCI-H358*
NCI-H378
NCI-H441
NCI-H441*
NCI-H446
NCI-H446*
NCI-H510A
NCI-H520
NCI-H520*
NCI-H522
NCI-H522*
NCI-H524
NCI-H524*
NCI-H526
NCI-H526*
NCI-H596
NCI-H596*
NCI-H64
NCI-H647
NCI-H647*
NCI-H650
NCI-H650*
NCI-H661
NCI-H661*
NCI-H69
NCI-H69*
NCI-H720
NCI-H727
NCI-H727*
NCI-H748
NCI-H810
NCI-H810*
NCI-H82
NCI-H82*
NCI-H838
NCI-H838*
NCI-H841


NCI-H841*
NCI-H847
PC-14
PC-14*
PC-3 [JPC-3]
RERF-LC-KJ
RERF-LC-KJ*
RERF-LC-MS
RERF-LC-MS*
RERF-LC-Sq1
RERF-LC-Sq1*
SBC-1
SBC-3
SBC-5
SBC-5*
SHP-77
SHP-77*
SK-LU-1
SK-LU-1*
SK-MES-1
SK-MES-1*
SW-1271
SW-1271*
SW-1573
SW-1573*
SW-900
SW-900*
VMRC-LCD
VMRC-LCD*
mesothelioma
NCI-H2369
NCI-H2373
NCI-H2461
NCI-H2591
NCI-H2595
NCI-H2722
NCI-H2731
NCI-H2795
NCI-H2803
NCI-H2804
NCI-H2810
NCI-H2818
NCI-H2869
NCI-H290
NCI-H513
IST-Mes1
MPP-89
MSTO-211H
NCI-H2052
NCI-H2452


NCI-H28
other
Calu-1
COR-L24
COR-L321
COR-L47
COR-L51
DFCI-024
DMS-153
DMS-454
DV-90
HCC-1171
HCC-1195
HCC-1359
HCC-1438
HCC-1588
HCC-1833
HCC-1897
HCC-2108
HCC-2279
HCC-2814
HCC-2935
HCC-33
HCC-364
HCC-4006
HCC-827-GR5
HCC-95
HLC-1
HLF-a
Hs-229.T
Hs-618.T
LC1F
Lu-99
LUDLU-1
MOR/CPR
NCI-H1184
NCI-H1339
NCI-H1373
NCI-H1385
NCI-H1437
NCI-H1618
NCI-H1930
NCI-H2081
NCI-H2106
NCI-H2126
NCI-H2171
NCI-H2286
NCI-H292
NCI-H292*
NCI-H3255
NCI-H460

NCI-H510																																											
NCI-H854																																											
NCI-H889																																											
RERF-LC-Ad1																																											
RERF-LC-Ad2																																											
RERF-LC-AI																																											
SALE																																											
SCLC-21H																																											
Sq-1																																											
T3-M10																																											
TIG-3TD																																											
VMRC-LCP																																											

color scale of activity - in the direction of decrease:

Table 4.14. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Lung: Part 2*

line cell	active anti-cancer molecular forms																																										
	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45								46	47	48	49	50	51		52	53		54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H						A	B		A	B			A	B
carcinoid-endocrine tumour																																											
NCI-H835																																											
UMC-11																																											
carcinoma																																											
201T																																											
A-427																																											
A-549																																											
A-549*																																											
ABC-1																																											
ABC-1*																																											
BEN																																											
BEN*																																											
CAL-12T																																											
CAL-12T*																																											
CAL-U3																																											
CAL-U3*																																											
CAL-U6																																											
CAL-U6*																																											
ChaGo-K-1																																											
ChaGo-K-1*																																											
COLO-668																																											
COLO-668*																																											
COR-L105																																											
COR-L105*																																											


COR-L23
COR-L23*
COR-L279
COR-L279*
COR-L303
COR-L311
COR-L311*
COR-L32
COR-L88
COR-L88*
COR-L95
COR-L95*
CPC-N
CPC-N*
DMS-114
DMS-114*
DMS-273
DMS-273*
DMS-53
DMS-53*
DMS-79
DMS-79*
EBC-1
EBC-1*
EKVX
EMC-BAC-1
EMC-BAC-2
EPLC-272H
EPLC-272H*
NCI-H3255
HARA
HARA*
HCC-15
HCC-15*
HCC-366
HCC-366*
HCC-44
HCC-44*
HCC-78
HCC-78*
HCC-827
HCC-827*
HOP-62
HOP-92
IA-LM
IA-LM*
IST-SL1
IST-SL2
KNS-62
KNS-62*
LB647-SCLC


LC-1/sq-SF
LC-1/sq-SF*
LC-2/ad
LCLC-103H
LCLC-103H*
LCLC-97TM1
LCLC-97TM1*
LK-2
LK-2*
LOU-NH91
LOU-NH91*
Lu-134A
Lu-135
Lu-139
Lu-165
Lu-65
Lu-65*
Lu-99A
LXF-289
LXF-289*
MS-1
NCI-H1048
NCI-H1048*
NCI-H1092
NCI-H1092*
NCI-H1105
NCI-H1105*
NCI-H1155
NCI-H1155*
NCI-H1299
NCI-H1299*
NCI-H1304
NCI-H1341
NCI-H1341*
NCI-H1355
NCI-H1355*
NCI-H1395
NCI-H1395*
NCI-H1417
NCI-H1435
NCI-H1435*
NCI-H1436
NCI-H1436*
NCI-H146
NCI-H146*
NCI-H1563
NCI-H1563*
NCI-H1568
NCI-H1568*
NCI-H1573


NCI-H1573*
NCI-H1581
NCI-H1581*
NCI-H1623
NCI-H1623*
NCI-H1648
NCI-H1648*
NCI-H1650
NCI-H1650*
NCI-H1651
NCI-H1651*
NCI-H1666
NCI-H1666*
NCI-H1688
NCI-H1693
NCI-H1693*
NCI-H1694
NCI-H1694*
NCI-H1703
NCI-H1703*
NCI-H1734
NCI-H1734*
NCI-H1755
NCI-H1755*
NCI-H1770
NCI-H1781
NCI-H1781*
NCI-H1792
NCI-H1792*
NCI-H1793
NCI-H1793*
NCI-H1836
NCI-H1836*
NCI-H1838
NCI-H1838*
NCI-H1869
NCI-H1869*
NCI-H187
NCI-H1876
NCI-H1876*
NCI-H1915
NCI-H1915*
NCI-H1944
NCI-H1944*
NCI-H196
NCI-H196*
NCI-H1963
NCI-H1963*
NCI-H1975
NCI-H1975*
NCI-H1993


NCI-H2009
NCI-H2009*
NCI-H2023
NCI-H2023*
NCI-H2029
NCI-H2029*
NCI-H2030
NCI-H2030*
NCI-H2066
NCI-H2066*
NCI-H2085
NCI-H2085*
NCI-H2087
NCI-H2087*
NCI-H209
NCI-H209*
NCI-H211
NCI-H211*
NCI-H2110
NCI-H2110*
NCI-H2122
NCI-H2122*
NCI-H2135
NCI-H2141
NCI-H2141*
NCI-H2170
NCI-H2170*
NCI-H2172
NCI-H2172*
NCI-H2196
NCI-H2196*
NCI-H2227
NCI-H2227*
NCI-H2228
NCI-H2228*
NCI-H226
NCI-H226*
NCI-H2291
NCI-H2291*
NCI-H23
NCI-H23*
NCI-H2342
NCI-H2342*
NCI-H2347
NCI-H2347*
NCI-H2405
NCI-H2405*
NCI-H2444
NCI-H2444*
NCI-H250


NCI-H292
NCI-H3122
NCI-H322*
NCI-H322M
NCI-H345
NCI-H358
NCI-H358*
NCI-H378
NCI-H441
NCI-H441*
NCI-H446
NCI-H446*
NCI-H510A
NCI-H520
NCI-H520*
NCI-H522
NCI-H522*
NCI-H524
NCI-H524*
NCI-H526
NCI-H526*
NCI-H596
NCI-H596*
NCI-H64
NCI-H647
NCI-H647*
NCI-H650
NCI-H650*
NCI-H661
NCI-H661*
NCI-H69
NCI-H69*
NCI-H720
NCI-H727
NCI-H727*
NCI-H748
NCI-H810
NCI-H810*
NCI-H82
NCI-H82*
NCI-H838
NCI-H838*
NCI-H841
NCI-H841*
NCI-H847
PC-14
PC-14*
PC-3 [JPC-3]
RERF-LC-KJ
RERF-LC-KJ*
RERF-LC-MS


RERF-LC-MS*
RERF-LC-Sq1
RERF-LC-Sq1*
SBC-1
SBC-3
SBC-5
SBC-5*
SHP-77
SHP-77*
SK-LU-1
SK-LU-1*
SK-MES-1
SK-MES-1*
SW-1271
SW-1271*
SW-1573
SW-1573*
SW-900
SW-900*
VMRC-LCD
VMRC-LCD*
mesothelioma
NCI-H2369
NCI-H2373
NCI-H2461
NCI-H2591
NCI-H2595
NCI-H2722
NCI-H2731
NCI-H2795
NCI-H2803
NCI-H2804
NCI-H2810
NCI-H2818
NCI-H2869
NCI-H290
NCI-H513
IST-Mes1
MPP-89
MSTO-211H
NCI-H2052
NCI-H2452
NCI-H28
other
Calu-1
COR-L24
COR-L321
COR-L47
COR-L51
DFCI-024


DMS-153
DMS-454
DV-90
HCC-1171
HCC-1195
HCC-1359
HCC-1438
HCC-1588
HCC-1833
HCC-1897
HCC-2108
HCC-2279
HCC-2814
HCC-2935
HCC-33
HCC-364
HCC-4006
HCC-827-GR5
HCC-95
HLC-1
HLF-a
Hs-229.T
Hs-618.T
LC1F
Lu-99
LUDLU-1
MOR/CPR
NCI-H1184
NCI-H1339
NCI-H1373
NCI-H1385
NCI-H1437
NCI-H1618
NCI-H1930
NCI-H2081
NCI-H2106
NCI-H2126
NCI-H2171
NCI-H2286
NCI-H292
NCI-H292*
NCI-H3255
NCI-H460
NCI-H510
NCI-H854
NCI-H889
RERF-LC-Ad1
RERF-LC-Ad2
RERF-LC-AI
SALE
SCLC-21H



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Lymphoma *(Lymphoma)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Lymphoma (***Tabl.4.15. a.*** & ***b.)***, it is concluded that:

- main potential medicines: ***AACF 1.C.***, ***4.C.***, ***5.B.***, ***5.C.***, ***5.D.***, ***12.***, ***19.***, ***23.A.***, ***31.B.***, ***34.***, ***39.***, ***40.***, ***45.E.***, ***51.A.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.G.***, ***4.A.***, ***5.A.***, ***7.***, ***25.***, ***30.***, ***31.A.***, ***31.C.***, ***32.***, ***33.***, ***36.***, ***37.***, ***38.***, ***41.***, ***42.***, ***43.***, ***44.***, ***45.B.***, ***46.***, ***47.***, ***48.***, ***49.***, ***50.***, ***51.B.*** and ***52***.

Table 4.15. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Lymphoma: Part 1*

cell line	active anti-cancer molecular forms																																										
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D															A	B			A	B						
lymphoid neoplasm																																												
A3/Kawakami																																													
A4/Fukuda																																												
BC-1																																												
BL-41																																												
CA-46																																												
CRO-AP2																																												
CTB-1																																												
Daudi																																												
DB																																												
DEL																																												
DG-75																																												


DoHH-2
EB-2
EB-3
EHEB
Farage
GA-10
GRANTA-519
H-9
HDLM-2
HD-MY-Z
Hs-445
JeKo-1
JiyoyeP-2003
JM-1
JSC-1
JVM-2
JVM-3
Karpas-1106P
Karpas-299
Karpas-422
KM-H2
L-1236
L-428
L-540
MC-116
Namalwa
NU-DUL-1
OCI-LY19
OCI-LY7
P32/ISH
Raji
Ramos-2G6-4C10
RC-K8
RL
RPMI-6666
SCC-3
SLVL
SR
ST-486
SU-DHL-1
SU-DHL-10
SU-DHL-16
SU-DHL-4
SU-DHL-5
SU-DHL-6
SUP-HD1
SUP-M2
TK
TUR
VAL
WIL2-NS

WSU-DLCL2	
WSU-NHL	
YT	
other	
SU-DHL-8	
color scale of activity - in the direction of decrease:	

Table 4.15. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Lymphoma: Part 2*

cell line	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45								46	47	48	49	50	51		52	53		54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H						A	B		A	B			A	B
lymphoid neoplasm																																											
A3/Kawakami																																											
A4/Fukuda																																											
BC-1																																											
BL-41																																											
CA-46																																											
CRO-AP2																																											
CTB-1																																											
Daudi																																											
DB																																											
DEL																																											
DG-75																																											
DoHH-2																																											
EB-2																																											
EB-3																																											
EHEB																																											
Farage																																											
GA-10																																											
GRANTA-519																																											
H-9																																											
HDLM-2																																											
HD-MY-Z																																											
Hs-445																																											
JeKo-1																																											
JiyoyeP-2003																																											
JM-1																																											
JSC-1																																											
JVM-2																																											
JVM-3																																											
Karpas-1106P																																											
Karpas-299																																											



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Myeloma *(Myeloma)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Myeloma (***Tabl.4.16. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 1.C.***, ***4.A.***, ***4.C.***, ***5.1.***, ***5.B.***, ***5.C.***, ***7.***, ***12.***, ***19.***, ***23.A.***, ***30.***, ***31.A.***, ***31.B.***, ***31.C.***, ***32.***, ***33.***, ***34.***, ***36.***, ***37.***, ***38.***, ***39.***, ***40.***, ***42.***, ***43.***, ***44.***, ***45.B.***, ***45.E.***, ***46.***, ***48.***, ***49.***, ***50.***, ***51.A.***, ***51.B.***, ***52.***, ***55.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 4.B.*** and ***25***.

Table 4.16. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Myeloma: Part 1*

cell line \ active anti-cancer molecular forms	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D															A	B			A	B						
lymphoid neoplasm																																												
AMO-1																																												
ARH-77																																												
EJM																																												
IM-9																																												
JJN-3																																												
Karpas-620																																												
KMS-11																																												
KMS-12-BM																																												
L-363																																												
LP-1																																												
MC/CAR																																												
MM.1S																																												
MOLP-8																																												
NCI-H929																																												
OPM-2																																												
RPMI-8226																																												
SK-MM-2																																												
U-266																																												

color scale of activity - in the direction of decrease:

Table 4.16. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Myeloma: Part 2*



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Neuroblastoma *(Neuroblastoma)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Neuroblastoma (***Tabl.4.17. a.*** & ***b.***), it is concluded that:

- main potential medicine: ***AACF 5.D.***, ***23.A.***, ***31.B.***, ***34.***, ***39.***, ***40.***, ***45.E.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.C.***, ***19.***, ***30.***, ***31.C.***, ***44.***, ***46.***, ***48.***, ***51.A.*** and ***56.A***.

Table 4.17. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Neuroblastoma: Part 1*

cell line	active anti-cancer molecular forms																																												
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D																A	B			A	B						
neuroblastoma																																														
BE(2)-M17																																														
CHP-126																																														
CHP-134																																														
CHP-212																																														
GI-ME-N																																														
GOTO																																														
IMR-5																																														
Kelly																																														
KP-N-YN																																														
LAN-6																																														
MHH-NB-11																																														
NB(TU)1-10																																														
NB-1																																														
NB-10																																														
NB-12																																														
NB-13																																														
NB-14																																														
NB-17																																														
NB-5																																														
NB-6																																														
NB-69																																														
NB-7																																														
NH-12																																														
SiMa																																														
SK-N-AS																																														
SK-N-DZ																																														
SK-N-FI																																														
SK-N-SH																																														
TGW																																														

color scale of activity - in the direction of decrease:

Table 4.17. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Neuroblastoma: Part 2*



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Nervous system *(Systema nervosum)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Nervous system (***Tabl.4.18. a.*** & ***b.)***, it is concluded that:

- main potential medicines: ***AACF 4.C.***, ***5.C.***, ***23.A.***, ***40.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 5.D.***, ***19.***, ***31.B.***, ***34.***, ***51.A.*** and ***56.A***.

Table 4.18. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Nervous system: Part 1*

cell line	active anti-cancer molecular forms																																										
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D																A	B			A	B					
glioma																																												
42-MG-BA																																												
8-MG-BA																																												
A-172																																												
AM-38																																												
Becker																																												
CAS-1																																												
CCF-STTG1																																												
D-247MG																																												
D-263MG																																												
D-336MG																																												
D-392MG																																												
D-423MG																																												
D-502MG																																												
D-542MG																																												
D-566MG																																												
DBTRG-05MG																																												
DBTRG-05MG*																																												
DK-MG																																												
DK-MG*																																												
GaMG																																												
GaMG*																																												
GB-1																																												
GB-1*																																												
GI-1																																												
GI-1*																																												
GMS-10																																												
H-4																																												
Hs-683																																												
KALS-1																																												


KINGS-1
KNS-42
KNS-81-FD
KS-1
LN-18
LN-229
LN-405
LNZTA3WT4
M-059J
MOG-G-CCM
MOG-G-UVW
NMC-G1
no-10
no-11
SF-126
SF-268
SF-295
SF-539
SK-MG-1
SNB-75
SW-1088
SW-1783
T98G
U-118MG
U-251
U-87MG
YH-13
YKG-1
primitive neuroectodermal tumour-medulloblastoma
D-283MED
Daoy
ONS-76
PFSK-1
color scale of activity - in the direction of decrease:

Table 4.18. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Nervous system: Part 2*





Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Oesophagus *(Oesophagus)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Oesophagus (***Tabl.4.19. a.*** & ***b.***) it is concluded that:

- main potential medicines: ***AACF 1.C.***, ***1.D.***, ***4.A.***, ***4.C.***, ***5.A.***, ***5.B.***, ***5.D.***, ***7.***, ***12.***, ***19.***, ***23.A.***, ***30.***, ***31.A.***, ***31.B.***, ***31.C.***, ***32.***, ***33.***, ***34.***, ***36.***, ***37.***, ***38.***, ***39.***, ***40.***, ***43.***, ***44.***, ***45.B.***, ***45.E.***, ***46.***, ***48.***, ***49.***, ***51.A.***, ***51.B.***, ***52.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.G.***, ***4.B.***, ***5.B.***, ***25.***, ***42.***, ***50.*** and ***53***.

Table 4.19. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Oesophagus: Part 1*

cell line	active anti-cancer molecular forms																																												
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D															A	B			A	B						
carcinoma																																													
OE-19																																													
TT																																													
other																																													
COLO-680N																																													
EC-GI-10																																													
JH-EsoAd1																																													
KYSE-140																																													
KYSE-150																																													
KYSE-180																																													
KYSE-270																																													
KYSE-30																																													
KYSE-410																																													
KYSE-450																																													
KYSE-510																																													
KYSE-520																																													
KYSE-70																																													
OE-33																																													
TE--1																																													
TE-10																																													
TE-11																																													
TE-14																																													
TE-15																																													
TE-4																																													
TE-5																																													
TE-6																																													
TE-8																																													
TE-9																																													

color scale of activity - in the direction of decrease:

Table 4.19. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Oesophagus: Part 2*



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Ovary *(Ovarium)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Ovary (***Tabl.4.20. a*** & ***b***), it is concluded that:

- main potential medicines: ***AACF 4.C.***, ***5.C.***, ***5.D.***, ***19.***, ***31.B.***, ***34.***, ***40.***, ***51.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.C.***, ***5.A.***, ***12.***, ***30.***, ***31.A.***, ***31.C.***, ***32.***, ***33.***, ***39.***, ***45.E.***, ***46.***, ***48.***, ***55.*** and ***56.A***.

Table 4.20. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Ovary: Part 1*

cell line	active anti-cancer molecular forms																																									
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D															A	B			A	B						
carcinoma																																												
A-2780																																												
Kuramochi																																												
OVISE																																												
OVKATE																																												
OVTOKO																																												
other																																												
59M																																												
Caov-3																																												
Caov-4																																												
COLO-704																																												
COV-318																																												
COV-362																																												
COV-434																																												
COV-504																																												
COV-644																																												
EFO-21																																												
EFO-27																																												
ES-2																																												
FU-OV-1																																												
HEY-A8																																												
Hc-571.T																																												
IGROV-1																																												
JHOC-5																																												
JHOM-1																																												
JHOM-2B																																												
JHOS-2																																												
JHOS-4																																												
MCAS																																												
NIH-OVCAR-3																																												



Table 4.20. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Ovary: Part 2*

cell line \ active anti-cancer molecular forms	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45									46	47	48	49	50	51		52	53		54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H						A	B		A	B			A	B
carcinoma																																										
A-2780																																										
Kuramochi																																										
OVISE																																										
OVKATE																																										
OVTOKO																																										
other																																										
59M																																										
Caov-3																																										
Caov-4																																										
COLO-704																																										
COV-318																																										
COV-362																																										
COV-434																																										
COV-504																																										



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Pancreas *(Pancreas)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Pancreas (***Tabl.4.21 a*** & ***b***), it is concluded that:

- main potential medicines: ***AACF 4.C.***, ***5.C.***, ***31.B.***, ***40.***, ***51.A.*** and ***56.B.;***
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.C.***, ***5.D.***, ***19.***, ***39.***, ***44.***, ***45.E.*** and ***56.A***.

Table 4.21. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Pancreas: Part 1*

cell line	active anti-cancer molecular forms																																										
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D															A	B			A	B					
carcinoma																																												
AsPC-1																																												
AsPC-1*																																												
BxPC-3																																												
BxPC-3*																																												
Capan-1																																												
Capan-1*																																												
Capan-2																																												
Capan-2*																																												
CFPAC-1																																												
CFPAC-1*																																												
DANG																																												
DANG*																																												
HPAC																																												
HPAC*																																												
HPAF-II																																												
HPAF-II*																																												
Hs-766T																																												
Hs-766T*																																												
HUP-T3																																												
HUP-T3*																																												
HUP-T4																																												
HUP-T4*																																												
KP-1N																																												
KP-3																																												
KP-3*																																												
KP-4																																												
KP-4*																																												
MIA-PaCa-2																																												
MIA-PaCa-2*																																												


MZ-1-PC
PANC-0203
PANC-0203*
PANC-0327
PANC-0327*
PANC-0403
PANC-0403*
PANC-0813
PANC-0813*
PANC-1005
PANC-1005*
PaTu-8902
PaTu -8902*
PaTu -8988T
PaTu -8988T*
PL-18
PL-4
PSN-1
PSN-1*
QGP-1
QGP-1*
SU-8686
SU-8686*
SUIT-2
SUIT-2*
SW-1990
SW-1990*
YAPC
YAPC*
other
KCI-MOH1
KLM-1
KP-2
KP-2*
L-33
PANC-0213
PANC-0504
PANC-1
PaTu-8988S
PK-1
PK-45H
PK-59
PL-45
SNU-213
SNU-324
SNU-410
T3M-4
TCC-Pan2
color scale of activity - in the direction of decrease:

Table 4.21. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Pancreas: Part 2*





Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Pleura *(Pleurae)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Pleura (***Tabl.4.22. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 1.C.***, ***1.D.***, ***1.G.***, ***4.A.***, ***4.B.***, ***4.C.***, ***5.A.***, ***5.B.***, ***5.C.***, ***5.D.***, ***7.***, ***12.***, ***19.***, ***23.A.***, ***30.***, ***31.A.***, ***31.B.***, ***31.C.***, ***32.***, ***33.***, ***34.***, ***36.***, ***37.***, ***38.***, ***39.***, ***40.***, ***42.***, ***43.***, ***44.***, ***45.B.***, ***45.E.***, ***46.***, ***48.***, ***49.***, ***50.***, ***51.A.***, ***52.B.***, ***55.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.A.***, ***11.***, ***25.*** and ***47***.

Table 4.22. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Pleura: Part 1*

cell line \ active anti-cancer molecular forms	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D															A	B			A	B						
other																																												
ACC-MESO-1																																												
DM-3																																												
IST-Mes-1																																												
IST-Mes-2																																												
JL-1																																												
MPP-89																																												
MSTO-211H																																												
NCI-H2052																																												
NCI-H2452																																												
NCI-H28																																												
RS-5																																												
color scale of activity - in the direction of decrease:																																												

Table 4.22. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Pleura: Part 2*

cell line \ active anti-cancer molecular forms	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45									46	47	48	49	50	51		52	53		54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H						A	B		A	B				A	B
other																																												
ACC-MESO-1																																												
DM-3																																												
IST-Mes-1																																												
IST-Mes-2																																												



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Prostate *(Prostata)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Prostate (***Tabl.4.23. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 1.C.***, ***4.C.***, ***5.A.***, ***5.D.***, ***12.***, ***19.***, ***23.A.***, ***31.A.***, ***31.B.***, ***34.***, ***39.***, ***40.***, ***45.E.***, ***48.***, ***51.A.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.D.***, ***1.G.***, ***4.A.***, ***4.B.***, ***5.B.***, ***7.***, ***25.***, ***30.***, ***31.C.***, ***32.***, ***33.***, ***36.***, ***37.***, ***38.***, ***42.***, ***43.***, ***44.***, ***45B.***, ***46.***, ***49.***, ***51.B.***, ***52.*** and ***55***.

Table 4.23. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Prostate: Part 1*



Table 4.23. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Prostate: Part 2*



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Salivary gland *(Glandulae salivariae oris)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Salivary grand (***Tabl.4.24. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF1.A.***, ***1.C.***, ***1.D.***, ***1.G.***, ***4.A.***, ***4.B.***, ***4.C.***, ***5.A.***, ***5.B.***, ***5.C.***, ***5.D.***, ***7.***, ***9.***, ***11.***, ***12.***, ***14.***, ***19.***, ***23.A.***, ***25.***, ***30.***, ***31.A.***, ***31.B.***, ***31.C.***, ***32.***, ***33.***, ***34.***, ***36.***, ***37.***, ***38.***, ***39.***, ***40.***, ***41.***, ***42.***, ***43.***, ***44.***, ***45.B.***, ***45.E.***, ***45.H.***, ***46.***, ***47.***, ***48.***, ***49.***, ***50.***, ***51.A.***, ***51.B.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.E.***, ***1.F.***, ***1.H.***, ***2.A.***, ***3.***, ***6.***, ***8.***, ***10.***, ***15.***, ***17.***, ***18.***, ***20.A.***, ***20.B.***, ***21.***, ***22.***, ***26.***, ***27.***, ***28.***, ***35.***, ***45.C.***, ***53.B.*** and ***54***.

Table 4.24. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Salivary gland: Part 1*



Table 4.24. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Salivary gland: Part 2*



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Skin *(Cutis)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Skin (***Tabl.4.25. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 4.C.***, ***5.C.***, ***5.D.***, ***19.***, ***31.B.***, ***34.***, ***39.***, ***40.***, ***45.E.***, ***51.A.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and/or substitution on medical grounds: ***AACF 1.C.***, ***5.A.***, ***11.***, ***12.***, ***30.***, ***31.A.***, ***31.C.***, ***33.***, ***37.***, ***44.***, ***45.B.***, ***46.***, ***48.***, ***49.***, ***51.B.*** and ***52***.

Table 4.25. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Skin: Part 1*

cell line	active anti-cancer molecular forms																																											
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D															A	B			A	B						
adnexal tumour																																													
DJM-1																																													
carcinoma																																													
A-388																																													
A-431																																													
malignant melanoma																																													
451-Lu																																													
A-101D																																													
A-101D*																																													
A-2058																																													
A-2058*																																													
A-375																																													
A-375*																																													
C-32																																													
C-32*																																													
CHL-1																																													
CHL-1*																																													
COLO-679																																													
COLO-679*																																													
COLO-783																																													
COLO-783*																																													
COLO-792																																													
COLO-792*																																													
COLO-800																																													
COLO-800*																																													
COLO-829																																													
COLO-829*																																													
CP50-MEL-B																																													
CP66-MEL																																													
G-361																																													
G-361*																																													
GAK																																													
G-MEL																																													
HMV-II																																													
Hs-940T																																													
Hs-940T*																																													
HT-144																																													
HT-144*																																													
IGR-1																																													
IGR-1*																																													
IGR-37																																													
IGR-37*																																													
IPC-298																																													
IPC-298*																																													


IST-MEL-1
K-2
LB2518-MEL
LB373-MEL-D
LOX-IMVI
LOX-IMVI*
M-14
MEL-HO
MEL-HO*
MEL-JUSO
MEL-JUSO*
MeWo
MeWo*
MMAc-SF
MZ2-MEL
MZ7-MEL
RPMI-7951
RPMI-7951*
RVH-421
RVH-421*
SH-4
SH-4*
SK-MEL-1
SK-MEL-1*
SK-MEL-2
SK-MEL-2*
SK-MEL-24
SK-MEL-24*
SK-MEL-28
SK-MEL-28*
SK-MEL-3
SK-MEL-3*
SK-MEL-30
SK-MEL-30*
SK-MEL-31
SK-MEL-31*
SK-MEL-5
SK-MEL-5*
UACC-257
UACC-257*
UACC-62
UACC-62*
WM-115
WM-115*
WM-1552C
WM-278
WM-35
WM-793B
other
BJ-hTERT

CJM
COLO-741
COLO-818
COLO-849
GR-M
HMCB
Hs-294T
Hs-600T
Hs-688AT
Hs-695T
Hs-834T
Hs-839T
Hs-852T
Hs-895T
Hs-934T
Hs-936T
Hs-939T
Hs-944T
IGR-39
K-029-AX
Malme-3M
MDA-MB-435S
WM-1799
WM-2664
WM-793
WM-88
WM-983B
color scale of activity - in the direction of decrease:

***Table 4.25. b** Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Skin: Part 2*

cell line	active anti-cancer molecular forms																																										
	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45								46	47	48	49	50	51		52	53		54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H						A	B		A	B			A	B
adnexal tumour																																											
DJM-1																																											
carcinoma																																											
A-388																																											
A-431																																											
malignant melanoma																																											
451-Lu																																											
A-101D																																											
A-101D*																																											
A-2058																																											
A-2058*																																											
A-375																																											


A-375*
C-32
C-32*
CHL-1
CHL-1*
COLO-679
COLO-679*
COLO-783
COLO-783*
COLO-792
COLO-792*
COLO-800
COLO-800*
COLO-829
COLO-829*
CP50-MEL-B
CP66-MEL
G-361
G-361*
GAK
G-MEL
HMV-II
Hs-940T
Hs-940T*
HT-144
HT-144*
IGR-1
IGR-1*
IGR-37
IGR-37*
IPC-298
IPC-298*
IST-MEL-1
K-2
LB2518-MEL
LB373-MEL-D
LOX-IMVI
LOX-IMVI*
M-14
MEL-HO
MEL-HO*
MEL-JUSO
MEL-JUSO*
MeWo
MeWo*
MMAc-SF
MZ2-MEL
MZ7-MEL
RPMI-7951
RPMI-7951*


RVH-421
RVH-421*
SH-4
SH-4*
SK-MEL-1
SK-MEL-1*
SK-MEL-2
SK-MEL-2*
SK-MEL-24
SK-MEL-24*
SK-MEL-28
SK-MEL-28*
SK-MEL-3
SK-MEL-3*
SK-MEL-30
SK-MEL-30*
SK-MEL-31
SK-MEL-31*
SK-MEL-5
SK-MEL-5*
UACC-257
UACC-257*
UACC-62
UACC-62*
WM-115
WM-115*
WM-1552C
WM-278
WM-35
WM-793B
other
BJ-hTERT
CJM
COLO-741
COLO-818
COLO-849
GR-M
HMCB
Hs-294T
Hs-600T
Hs-688AT
Hs-695T
Hs-834T
Hs-839T
Hs-852T
Hs-895T
Hs-934T
Hs-936T
Hs-939T
Hs-944T
IGR-39



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Small intestine *(Intestinum tenue)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Small intestine (***Tabl.4.26. a.*** & ***b.***) it is concluded that:

- main potential medicines: ***AACF 1.C.***, ***4.C.***, ***5.A.***, ***5.C.***, ***5.D.***, ***19.***, ***23.A.***, ***31.B.***, ***31.C.***, ***32.***, ***34.***, ***39.***, ***40.***, ***45.E.***, ***51.A.***, ***51.B.***, ***52.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.A.***, ***1.D.***, ***1.G.***, ***4.A.***, ***4.B.***, ***5.B.***, ***7.***, ***9.***, ***11.***, ***12.***, ***14.***, ***25.***, ***30.***, ***31.A.***, ***33.***, ***36.***, ***37.***, ***38.***, ***41.***, ***42.***, ***43.***, ***44.***, ***45.B.***, ***45.H.***, ***46.***, ***47.***, ***48.***, ***49.***, ***50*** and ***55***.

Table 4.26. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Small intestine: Part 1*



Table 4.26. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Small intestine: Part 2*



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Soft tissue *(Mollis textus)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Soft tissue (***Tabl.4.27. a*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 1.C.***, ***4.B.***, ***5.C.*** and ***40.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.D.***, ***4.C.***, ***5.D.***, ***12.***, ***19.***, ***23.A.***, ***30.***, ***31.A.***, ***31.B.***, ***31.C.***, ***32.***, ***33.***, ***34.***, ***36.***, ***37.***, ***38.***, ***39.***, ***42.***, ***43.***, ***44.***, ***45.B.***, ***45.E.***, ***46.***, ***48.***, ***49.***, ***51.A.***, ***51.B.***, ***56.A.*** and ***56.B***.

Table 4.27. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Soft tissue: Part 1*




SW-872
malignant fibrous histiocytoma-pleomorphic sarcoma
GCT
GCT*
MFH-ino
rhabdomyosarcoma
A-204
A-204*
KYM-1
KYM-1*
RD
RD*
RH-1
RH-18
RH-18*
RH-41
RH-41*
SJRh-30
SJRh-30*
TE-441.T
TE-441.T*
sarcoma
SKLMS1
SKLMS1*
VA-ES-BJ
synovial sarcoma
SW-982
other
G-401
Hs-633T
Hs-729
MES-SA
Rh-30
RKN
S-117
STS-0421
TE-125.T
TE-159.T
TE-617.T
color scale of activity - in the direction of decrease:

***Table 4.27. b** Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Soft tissue: Part 2*

	active anti-cancer molecular forms																																										
cell line	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45								46	47	48	49	50	51		52	53		54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H						A	B		A	B			A	B
Ewings sarcoma-peripheral primitive neuroectodermal tumour																																											
A-673																																											
fibrosarcoma																																											
HT-1080																																											
HT-1080*																																											
SW-684																																											
leiomyoblastoma																																											
G-402																																											
G-402*																																											
leiomyosarcoma																																											
SK-UT-1																																											
SK-UT-1*																																											
liposarcoma																																											
SW-872																																											
malignant fibrous histiocytoma-pleomorphic sarcoma																																											
GCT																																											
GCT*																																											
MFH-ino																																											
rhabdomyosarcoma																																											
A-204																																											
A-204*																																											
KYM-1																																											
KYM-1*																																											
RD																																											
RD*																																											
RH-1																																											
RH-18																																											
RH-18*																																											
RH-41																																											
RH-41*																																											
SJRh-30																																											
SJRh-30*																																											
TE-441.T																																											
TE-441.T*																																											
sarcoma																																											
SKLMS1																																											
SKLMS1*																																											
VA-ES-BJ																																											
synovial sarcoma																																											
SW-982																																											
other																																											
G-401																																											
Hs-633T																																											
Hs-729																																											



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Stomach *(Stomachus)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Stomach (***Tabl.4.28. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 1.C.***, ***4.C.***, ***5.A.***, ***5.C.***, ***5.D.***, ***12.***, ***19.***, ***23.A.***, ***30.***, ***31.A.***, ***31.B.***, ***31.C.***, ***33.***, ***34.***, ***36.***, ***37.***, ***38.***, ***39.***, ***40.***, ***43.***, ***44.***, ***45.B.***, ***45.E.***, ***46.***, ***48.***, ***49.***, ***51.A.***, ***51.B.***, ***52.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and/or substitution on medical grounds: ***AACF 1.G.***, ***4.A.***, ***4.B.***, ***5.B.***, ***7.***, ***25.***, ***32.***, ***50.*** and ***55***.

Table 4.28. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Stomach: Part 1*

cell line	active anti-cancer molecular forms																																														
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D															A	B			A	B						
carcinoma																																														
AGS																																														
ECC-10																																														
ECC-12																																														
FU-97																																														
GCIY																																														
KATO-III																																														
MKN-1																																														
MKN-45																																														
MKN-7																																														



Table 4.28. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Stomach: Part 2*

cell line \ active anti-cancer molecular forms	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45								46	47	48	49	50	51		52	53		54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H						A	B		A	B			A	B
carcinoma																																										
AGS																																										
ECC-10																																									
ECC-12																																									
FU-97																																									
GCIY																																									
KATO-III																																									



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Thyroid *(Glandula thyreoidea)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Thyroid (***Tabl.4.29. a.*** & ***b.)***, it is concluded that:

- main potential medicines: ***AACF 5.C.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 1.C.***, ***4.C.***, ***5.D.***, ***23.***, ***31.B.***, ***34.***, ***39.***, ***40.***, ***45.E.***, ***48.*** and ***51.A***.

Table 4.29. a Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Thyroid: Part 1

cell line \ active anti-cancer molecular forms	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D															A	B									
carcinoma																																												
8305-C																																												
8305-C*																																												
8505-C																																												
8505-C*																																												
ASH-3																																												
B-CPAP																																												
B-CPAP*																																												
BHT-101																																												
BHT-101*																																												
CAL-62																																												
CAL-62*																																												
CGTH-W1																																												
CGTH-W1*																																												
FTC-133																																												
FTC-133*																																												
HTC-C3																																												
IHH-4																																												
K5																																												
ML-1																																												
ML-1*																																												
RO82-W-1																																												
TT																																												
TT*																																												
TT2609-C02																																												
TT2609-C02*																																												
other																																												
FTC-238																																												
SW-579																																												
color scale of activity - in the direction of decrease:																																												

Table 4.29. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Thyroid: Part 2*



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Upper aerodigestive tract *(Tractus superior aerodigestive)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Upper aerodigestive tract (***Tabl.4.30. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 1.C.***, ***1.D.***, ***4.C.***, ***5.A.***, ***5.B.***, ***5.C.***, ***5.D.***, ***7.***, ***12.***, ***19.***, ***23.A.***, ***30.***, ***31.A.***, ***31.B.***, ***31.C.***, ***32.***, ***33.***, ***34.***, ***36.***, ***37.***, ***38.***, ***39.***, ***40.***, ***43.***, ***44.***, ***45.B.***, ***45.E.***, ***46.***, ***48.***, ***49.***, ***51.A.***, ***51.B.***, ***52.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 4.A.***, ***42.***, ***50.*** and ***55***.

Table 4.30. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Upper aerodigestive tract: Part 1*



SNU-1214																																												
SNU-46																																												
SNU-899																																												
YD-10B																																												
YD-38																																												
YD-8																																												

color scale of activity - in the direction of decrease:						

***Table 4.30. b** Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Upper aerodigestive tract: Part 2*

	active anti-cancer molecular forms																																										
cell line	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45								46	47	48	49	50	51		52	53		54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H						A	B		A	B			A	B
carcinoma																																											
BHY																																											
BICR-22																																											
BICR-31																																											
FaDu																																											
other																																											
BICR-16																																											
BICR-18																																											
BICR-56																																											
BICR-6																																											
CAL-27																																											
CAL-33																																											
Detroit-562																																											
Hs-840.T																																											
HsC-2																																											
HSC-3																																											
HSC-4																																											
PE/CA-PJ15																																											
PE/CA-PJ34 clone C12																																											
PE/CA-PJ41cloned2																																											
PECA-PJ49																																											
SCC-15																																											
SCC-25																																											
SCC-4																																											
SCC-9																																											
SNU-1041																																											
SNU-1066																																											
SNU-1076																																											
SNU-1214																																											
SNU-46																																											
SNU-899																																											

Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Urinary tract *(Tractus urinarii)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Urinary tract (***Tabl.4.31. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 1.C.***, ***1.D.***, ***1.G.***, ***4.A.***, ***4.B.***, ***4.C.***, ***5.A.***, ***5.B.***, ***5.C.***, ***5.D.***, ***7.***, ***12.***, ***19.***, ***23.A.***, ***25.***, ***30.***, ***31.A.***, ***31.B.***, ***31.C.***, ***32.***, ***33.***, ***34.***, ***36.***, ***37.***, ***38.***, ***39.***, ***40.***, ***43.***, ***44.***, ***45.B.***, ***45.E.***, ***46.***, ***48.***, ***49.***, ***50.A.***, ***50.B.***, ***52.***, ***56.A.*** and ***56.B.***;
- duplication of treatment and / or substitution on medical grounds: ***AACF 9.***, ***42.***, ***47.***, ***50.*** and ***55***.

Table 4.31. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Urinary tract: Part 1*





Table 4.31. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Urinary tract: Part 2*

cell line \ active anti-cancer molecular forms	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45								46	47	48	49	50	51		52	53		54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H						A	B		A	B			A	B
carcinoma																																										
5637																																									
J-82																																									
RT-4																																									
SW-1710																																									
SW-780																																									
TCCSUP																																									
other																																									
253-J																																									
253-JBV																																									
639-V																																									
647-V																																									
BC-3C																																									
BFTC-905																																									
CAL-29																																									
Hs-172.T																																									
HT-1197																																									
HT-1376																																									
JM(SU)-1																																									
KMBC-2																																									
KU-1919																																									
RT-112																																									
RT-11284																																									
SCaBER																																									
T-24																																									
UB-LC-1																																									

Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

Urogenital system *(Systema urogenitale)*

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (***Tabl. 2***) of transcriptome cell lines inherent in tumors in the Urogenital system (***Tabl.4.32. a.*** & ***b.***), it is concluded that:

- main potential medicines: ***AACF 4.C.***, ***5.C.***, ***23.***, ***33.***, ***40.***, ***51.A.***, ***51.B.*** *and* ***56.***;
- duplication of treatment and/or substitution on medical grounds: ***AACF 1.C.***, ***5.D.***, ***19.***, ***31.B.***, ***34.***, ***39.***, ***44.***, ***45.A.***, ***45.E.***, ***46.***, ***48.***, ***51.A.*** and ***56.A.***

Table 4.32. a *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Urogenital system: Part 1*

cell line	active anti-cancer molecular forms																																														
	1								2			3	4			5				6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	22	23		24	25	26	27	28
	A	B	C	D	E	F	G	H	A	B	C		A	B	C	A	B	C	D															A	B			A	B						
carcinoma																																														
5637																																														
22Rv1																																														
639-V																																														
647-V																																														
A-2780																																														
AN3-CA																																														
BFTC-905																																														
C-33 A																																														
C-4-I																																														
CAL-29																																														
CAL-39																																														
Caov-4																																														
Ca-Ski																																														
COLO-684																																														
DoTc2-4510																																														
DOV-13																																														
DSH1																																														
DU-145																																														


EFO-21
EFO-27
EN
ES-2
ESS-1
FU-OV-1
HEC-1
HeLa
Hey
HT-1197
HT-1376
HT-3
IGROV-1
J82
JHOS-2
JHOS-3
JHOS-4
KLE
KU-19-19
Kuramochi
LB831-BLC
LNCaP clone FGC
ME-180
MFE-280
MFE-296
MFE-319
MS-751
OAW-28
OAW-42
OC-314
OV-17R
OV-56
OV-7
OV-90
OVCA-420
OVCAR-3
OVCAR-4
OVCAR-5
OVCAR-8
OVISE
OVK-18
OVKATE
OVMIU
OVTOKO
PC-3
PEO-1
RL95-2
RMG-I
RT-112
RT4


SiHa
SISO
SKG-IIIa
SK-OV-3
SNG-M
SW-1710
SW-626
SW-756
SW-780
SW-954
SW-962
T-24
TCCSUP
TC-YIK
TOV-112D
TOV-21G
TYK-nu
UM-UC-3
UWB1.289
VCaP
VM-CUB-1
choriocarcinoma
JAR
JEG-3
germ cell tumour
NEC8
NTERA-2 cl.D1
PA-1
hyperplasia
BPH-1
leiomyosarcoma
SKN
sarcoma
MES-SA
sex cord-stromal tumour
KGN
other
PWR-1E
RKN
color scale of activity - in the direction of decrease:

Table 4.32. b *Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Urogenital system: Part 2*

cell line	active anti-cancer molecular forms																																									
	29				30	31			32	33	34	35	36	37	38	39	40	41	42	43	44	45								46	47	48	49	50	51		52	53		54	55	56	
	A	B	C	D		A	B	C														A	B	C	D	E	F	G	H						A	B		A	B			A	B
carcinoma																																										
5637																																										
22Rv1																																										
639-V																																										
647-V																																										
A-2780																																										
AN3-CA																																										
BFTC-905																																										
C-33 A																																										
C-4-I																																										
CAL-29																																										
CAL-39																																										
Caov-4																																										
Ca-Ski																																										
COLO-684																																										
DoTc2-4510																																										
DOV-13																																										
DSH1																																										
DU-145																																										
EFO-21																																										
EFO-27																																										
EN																																										
ES-2																																										
ESS-1																																										
FU-OV-1																																										
HEC-1																																										
HeLa																																										
Hey																																										
HT-1197																																										
HT-1376																																										
HT-3																																										
IGROV-1																																										
J82																																										
JHOS-2																																										
JHOS-3																																										
JHOS-4																																										
KLE																																										
KU-19-19																																										
Kuramochi																																										
LB831-BLC																																										
LNCaP clone FGC																																										
ME-180																																										
MFE-280																																										


MFE-296
MFE-319
MS-751
OAW-28
OAW-42
OC-314
OV-17R
OV-56
OV-7
OV-90
OVCA-420
OVCAR-3
OVCAR-4
OVCAR-5
OVCAR-8
OVISE
OVK-18
OVKATE
OVMIU
OVTOKO
PC-3
PEO-1
RL95-2
RMG-I
RT-112
RT4
SiHa
SISO
SKG-IIIa
SK-OV-3
SNG-M
SW-1710
SW-626
SW-756
SW-780
SW-954
SW-962
T-24
TCCSUP
TC-YIK
TOV-112D
TOV-21G
TYK-nu
UM-UC-3
UWB1.289
VCaP
VM-CUB-1
choriocarcinoma
JAR
JEG-3
germ cell tumour



Other pharmaceutical forms would be highly active and potential agents for personalized therapies.

RESULTS ANALYSIS

In ***Fig.1*** present (*§III.3.4.2, Tsanov & Tsanov, 2023*) the descriptive dependences of the interpretable predictions of sensitivity to active anti-cancer molecular forms of transcriptional cell lines inherent in tumors of different nature.



Figure 1 *Schematic representation of the descriptive dependences of the interpretable predictions of sensitivity to active anti-cancer molecular forms of transcriptomal cell lines inherent in tumors*

They highlight some molecular forms that are extremely active. These are: for basic pharmaceutical forms /sorted by total activity/ – ***40.***, ***56.B.***, ***5.C.***, ***4.C.***, ***51.A.***, ***5.D.***, ***19.***, ***31.B.***, ***56.A.***, ***34.***, ***23.A.***, ***1.C.*** and ***45.E.***; for substitute forms – ***48.***, ***55.***, ***1.D.***, ***4.A.***, ***4.B.***, ***32.***, ***42.***, ***25.***, ***31.C.*** and ***46***.

The final breakdown by active group and pharmaceutical form is presented in the front section.

CLINICAL CONTROL

Correlation of bio constants

The bio constants of the human organism should not be accepted as a dogma, but simply used as benchmarks of the norm. Deviation from them should not necessarily be considered pathology. The human body adapts extremely well to the environment and strives to respond adequately to each stimulus.

Especially when performing chemotherapy on cancer patients, it is necessary to monitor the overall reference picture of the patient. It is good to avoid interpreting individual deviations from the physiologically healthy organism and to direct the treatment of cancer in the direction of "suppression" of individual symptoms.

In ***Tabl. 5*** the control forms that the clinician must comply with before and during chemotherapy are indicated. These are reference correlations that would directly affect the release of the active anticancer molecular form (***Tabl. 2***) within the cancer cell.

A. **VOLUME OF BLOOD**: it is directly related to the fluid ratio, and secondarily to the water content in the body - hence the change in a number of physicochemical parameters

When the total blood volume increases, it is important for the treating physician to rule out diagnoses:

- chronic leucosis;
- uremia (due to the change in nitrogen balance, which will prevent the transport of amide derivatives in the body) - is often accompanied by hyperkalemia and hyperchloremia.

When the total blood volume decreases, it is necessary to exclude the diagnoses:

- acidosis - increased water content is also reported;
- tubular acidosis - IMPORTANT: do not rush with tenal tubular acidosis - there may also be hypophosphatemia.

B. **HEMATOCRIT**:

In case of a decrease in the value of the hematocrit in the blood, it is obligatory for the attending physician to reject the diagnoses:

- spherocytic anemia - at the beginning of treatment with amide / carboxylic derivative of nitrile glycosides there is a !!! **REAL POSSIBILITY FOR CRISIS** !!! ;
- this condition is often an indicator of brain metastases.

C. NATREMIA:

Particular attention should be paid to cases of hyponatremia. Here the attending physician needs to comply with diagnoses such as:

- cystic fibrosis (CP) / mucoviscidose/- in these cases treatment should begin with a very low concentration of the dosage form;
- this condition is often an indicator of lung cancer.

D. KALEMIA:

To some extent, hyperkalemia has a synergistic effect on the action of the studied dosage forms. It is good for the doctor to maintain higher blood potassium reference values. In cases where this is difficult, two circumstances must be taken into account:

- to reject Cushing's syndrome, by control test and for hyperchloremia - gives both increase and decrease;
- is often observed together with hypophosphatemia. If necessary, to introduce phosphorus preparations into the body.

E. CHLORAEMIA:

Hypochloraemia alters the ionic and electrostatic activity of both amides and carboxylic acids - especially when they are in low concentrations in the blood. It is good to consider:

- presence of liver cirrhosis - the analysis should be done at least 4 hours after glucose infusion and diuretics taken. The results should be differentiated from Hepato-renal syndrome.

F. CALCEMIA:

Hypercalcemia can suppress the spread of the drug form. Treatment should be resected and any comorbidities considered:

- extensive metastases;
- osteorenal sarcoma;
- breast carcinoma with bone metastases during treatment with ANDROGENS and ESTRONES;
- sarcoidosis.

G. SIDERINEMIA:

Hyposiderinemia could delay the detection of a more acidic environment around the cancer cell and from there slow down the action of the drug under study. The clinician should be aware that this is often accompanied by:

- ballast leukemia;
- carcinomas;
- uterine fibroids;
- myelosis and lymphadenosis (in terminal stage);
- erythraemia vera (in terminal stage).

Correction of iron in the blood is one of the most important factors in treatment with these doses.

Table 5 *Correlation data of microcomponents in human blood that affect the digestibility and activity of amides and carboxylic acids derivatives of natural nitrile glycosides*

control form	raise		reduction	
	indicator	indicator control	indicator	indicator control
volume of blood	chronic leucosis		acidosis	increased water content is also reported
			tubular acidosis*	hypophosphatemia
	uremia⁑	hyperkalemia		
		hyperchloremia		
hematocrit			spherocytic anemia ☼	
			indicator of brain metastases	
natremia▲			Mucoviscidose ⁂	
			indicator of lung cancer	
kalemia			to reject Cushing's syndrome◊	
			often seen with hypophosphatemia	
chloraemia			indicator and of liver cirrhosis§	
calcemia	extensive metastases			
	osteorenal sarcoma			
	breast carcinoma with bone metastases during treatment with ANDROGENS and ESTROGENES			
	sarcoidosis			
siderinemia			ballast leukemia	
			carcinomas	
			uterine fibroids	
			myelosis and lymphadenosis (in terminal stage)	
			erythraemia vera (in terminal stage)	
total iron-binding capacity	bone marrow hypoplasia		hemosiderosis	
			malignant tumors	
cupremia	malignant tumors	increase in iodine in the blood		
	malignant melanoma			
	hemochromatosis			
	malignant hemopathy (T-leucosis)	increase of sulfates in the blood		
	meligenic lymphomas			
	treatment with estrogen			
	cirrhosis of the liver	reduction of iodine in the blood		
Zinc content in the blood	in the serum			
	erythraemia vera		bone marrow hypoplasia	
	atrophic cirrhosis of the liver		lymphadenosis	
	acute leucosis		myelosis	
	in erythrocytes			

	bone marrow hypoplasia	myelosis
	erythraemia vera	lifadenosis

*- IMPORTANT: do not rush with tenal tubular acidosis - there may also be hypophosphatemia
⁂- due to a change in the nitrogen balance
☼- **REAL POSSIBILITY FOR CRISIS !**
⁂- MANDATORY- the treatment should begin with a very low concentration of the dosage form
▲- to rule out myxedema as a concomitant disease
◊- control test and for hyperchloremia - gives both increase and decrease
§- the analysis should be performed at least 4 hours after glucose infusion and diuretics taken. The results should be differentiated from Hepato-renal syndrome

H. TOTAL IRON-BINDING CAPACITY

In case of increased content of total iron-binding capacity, it is necessary for the clinician to take into account the possible presence of:

- bone marrow hypoplasia,

and at reduced content with:

- hemosiderosis;
- malignant tumors.

I. CUPREMIA:

Hypercupremia would significantly increase the need for a higher drug dose. She herself is also an indicator for:

- malignant tumors - as an control sample can be used and the increase in iodine in the blood; - malignant melanoma;
- hemochromatosis;
- malignant hemopathy (T-leukemia) - as an control sample can be used and the increase of sulfates in the blood;
- meligenic lymphomas;
- treatment with estrogen;
- cirrhosis of the liver - as a control sample can be used and the reduction of iodine in the blood.

J. ZINC CONTENT IN THE BLOOD

The content of zinc in the blood determines its extremely complex role in cancer. Its compounds are both inhibitors and promoters. It can displace a number of metals from organometallic biologically active substances, but at the same time its coordination compounds in an in vivo medium are volatile.

We recommend a mandatory blood test for zinc in the blood before starting chemotherapy according to the studied experimental methodology. The following reference deviations must be taken into account:

a. in the serum:

increased serum zinc concentration:	**decreased serum zinc concentration:**
- erythraemia vera; - atrophic cirrhosis of the liver; - acute leukemia.	- bone marrow hypoplasia; - lymphadenosis; - myelosis.

b. in erythrocytes:

increased concentration of zinc in erythrocytes:	**decreased concentration of zinc in erythrocytes:**
- bone marrow hypoplasia; - erythraemia vera.	- myelosis; - lifadenosis.

Chemoprevention and Homeopathy

The proposed methodological program for conservative treatment of oncological diseases does not contradict the good medical practices for chemotherapy. In order to improve the general condition of patients, chemoprevention (Lele, 2021) and/or homeopathy could be applied, but not at the expense of a varied diet, incl. table salt, water, culinary acidifiers and fats. Alternative medicine should only be used to treat individual symptoms, not syndromes.

- ◊ -

THE CONCLUSIONS OF THE PREVIOUS STUDIES

On the first goal (Tsanov & Tsanov, 2020)

Our legacy of the *Hunza people* and the knowledge from tens-of-thousands of scientists who created modern synthesis and biochemistry make the production of nitrile amide into a routine (especially with nitrile hydratase). Thus, humanity holds in its hands a huge medicinal resource that can provide treatment for diseases of all parts of conservative medicine (including all listed in ***Section 1.1***.).

The hydrolyzed to amide/carboxylic acid nitrile/cyanide carbohydrates will occupy one of the fundamental steps of countless future clinical practices. This is the purpose of our modest research!

Other substances in these groups with pronounced biological activity (including anti-tumor) are the hydrolyzed nitrile groups of ***Linamarin***, ***(R) -Lotaustralin***, ***S-Sambunigrin***, etc., to their amide/carboxylic acid.

The second goal (Tsanov & Tsanov, 2021)

1) The amide derivatives of nitrile glycosides are potential chemical compounds with anti-cancer activity;

2) the cancer cell seeks to shift the hydrolysis of these derivatives in a direction that would not pass through its cell membrane;

3) the amide-carboxylic derivatives of nitrile glycosides can deliver extremely toxic compounds inside the tumor cell itself and thus block and / or permanently damage its normal physiology;

4) the use of these compounds in oncology could turn cancer from a lethal to a chronic disease (such as diabetes). The cause and conditions of the disease are not eliminated, but the number of cancer cells could be kept low for a long time (even a lifetime).

On the third goal (Tsanov & Tsanov, 2022)

1) Amides resulting from the hydrolysis of nitrile glycosides would be able to cross the cell membrane of a cancer cell and thus cause its cellular response;

2) the pharmaceutical form must represent the exact amide/carboxylic acid ratio for the corresponding active anticancer cell form;

3) clinical concentrations are more than 7 times higher than those of nitrile glycosides due to their reduced toxicity;

4) no significant deviations are observed, on a theoretical level, in the complex use of several pharmaceutical forms together and/or sequentially.

APPLYING THE RESULTS

The results of the analysis show that the studied molecular forms do NOT contradict conservative oncology. Their activity is significant and many times exceeds a number of approved products for treatment (*§IV.3.2., p.718;* Tsanov & Tsanov, 2023) (Tsanov & Tsanov, 2022).

This anti-cancer agents could best be administered orally (*§IV.1., p.57;* Tsanov & Tsanov, 2023).. Their toxicity is many times less than that of most references accepted in clinical chemotherapy (*§IV.3.1., p.85;* Tsanov & Tsanov, 2023) (Tsanov & Tsanov, 2020).

After analyzing the conclusions on the previous goals of the research (*§IV.1÷3., p.718;* Tsanov & Tsanov, 2023) (Tsanov & Tsanov, 2021), taking into account the presented clinical control, the data for the interpretable prognosis for susceptibility to active anti-cancer molecular forms of transcriptome cell lines inherent in tumors - for each anatomical system, good medical practices and the data from ***Fig. 1.***, we conclude that the treatment of oncological diseases should be carried out in four stages (***Fig.2.***):



Figure 2 *Schematic representation of the sequence of treatment with amide and carboxyl derivatives of natural nitrile glycosides of cancer cell lines*

- "shock therapy" - in the case of a primary diagnosis of the presence of oncological disease and/or observation of pathological activity of cancer cells (including the growth of tumor tissues), the patient should be treated with:



(R)-2-phenyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)acetamide

(R)-2-phenyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)acetic acid

Thus, the active anticancer molecule released inside the cell itself will be *((R)-2-hydroxy-2-phenylacetamide*, which in turn would pass in a small amount into the carboxyl form - *(R)-2-hydroxy-2-phenylacetic acid* (*§IV.2.3.2.*). Applying pharmaceutical form ***1.B.*** (***Tabl. 1.***), the concentration of the amide toxic to the cancer cell is 0.40 *mg/ml*, compared to the pharmaceutical oral form (*§IV.2. 4.*, Tsanov & Tsanov, 2023). Based on the analysis for determining the medicinal dose of the amide and carboxylic derivatives of amygdalin (*§IV.1. 3.*, Tsanov & Tsanov, 2023), it follows that the treatment dose for the ratio, **-amide: -carboxylic = 4.87: 1** is:

210-465 *mg PO q6-8hr*; not to exceed 2.1 *g/day*.

!!! If the patient shows allergic symptoms, he should undergo diuretic cleansing, after consultation with a nephrologist - after which the treatment should be started again. If similar symptoms appear again, this stage of treatment can be skipped **!!!**

- primary treatment – after making the final diagnosis and determining the exact active cell lines, the clinical oncologist must proceed to the actual treatment - **Introduction of the main active pharmaceutical form into the body**.

This concept includes clinical selection from a pre-calculated set of substances active enough to influence the physiological activity of the cancer cell. This stage aims to "attack" the cancer cells in a wider range of cell lines, incl. those that overlap with other cancer formations (including metastases), which at this moment may be in another stage of their development. The choice is made between the chemical compounds from the ***Tabl. 6***.

Table 6 *Basic pharmaceutical forms for oral use for primary treatment of cancer, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides*

login number*	active pharmaceutical forms for oral use**	UPAC component names***
40.		(Z)-2-((2S,3R,4S,6R)-2,3-dihydroxy-4-methoxy-6-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexylidene)acetamide
		(Z)-2-((2S,3R,4S,6R)-2,3-dihydroxy-4-methoxy-6-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexylidene)acetic acid
56.B.		((2R,3S,4S,5R,6R)-6-(((2S,3R)-4-amino-3-methyl-4-oxobutan-2-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl (2S,3R)-2-ethyl-2,3-dihydroxybutanoate
		(2R,3S)-3-(((2R,3R,4S,5S,6R)-6-((((2S,3R)-2-ethyl-2,3-dihydroxybutanoyl)oxy)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-2-methylbutanoic acid

5.C.		(R)-2-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)butanamide (R)-2-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)butanoic acid
4.C.		2-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)propanamide 2-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)propanoic acid
51.A.		(Z)-2-(hydroxymethyl)-4-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)but-2-enamide (Z)-2-(hydroxymethyl)-4-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)but-2-enoic acid
5.D.		(R)-2-(((2S,3R,4S,5S,6R)-6-((((2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-2-methylbutanamide (R)-2-(((2S,3R,4S,5S,6R)-6-((((2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-2-methylbutanoic acid
19.		(2S,3S)-2-hydroxy-4-methoxy-1-methyl-6-oxo-3-(((2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,2,3,6-tetrahydropyridine-3-carboxamide (2S,3S)-2-hydroxy-4-methoxy-1-methyl-6-oxo-3-(((2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,2,3,6-tetrahydropyridine-3-carboxylic acid

31.B.		(R)-2-(3-hydroxy-4-methoxyphenyl)-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)acetamide (R)-2-(3-hydroxy-4-methoxyphenyl)-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)acetic acid
56.A.		((2R,3S,4S,5R,6R)-6-(((2R,3S)-4-amino-3-methyl-4-oxobutan-2-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl (2S,3R)-2-ethyl-2,3-dihydroxybutanoate (2S,3R)-3-(((2R,3R,4S,5S,6R)-6-((((2S,3R)-2-ethyl-2,3-dihydroxybutanoyl)oxy)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-2-methylbutanoic acid
34.		(R)-3-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)but-3-enamide (R)-3-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)but-3-enoic acid
23.A.		2-(3-hydroxy-4-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)phenyl)acetamide 2-(3-hydroxy-4-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)phenyl)acetic acid
1.C.		(R)-2-phenyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)acetamide (R)-2-phenyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)acetic acid

45.E.		(2R,3R,4S,5R,6R)-2-(((Z)-4-amino-2-methyl-4-oxobut-2-en-1-yl)oxy)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl acetate (Z)-4-(((2R,3R,4S,5R,6R)-4-acetoxy-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-methylbut-2-enoic acid

*- sorted by general activity - descending
- this table represents a sample of ***Tabl. 2* and the data from ***§IV.4. 2.*** of ***(Tsanov & Tsanov, 2023)***
⁂- it is the most active isomeric molecular form. Any kind of optical isomerism is allowed.

The clinical approach here requires the selection of an active pharmaceutical form (***Tabl. 6***) against the Interpretable prediction of sensitivity to active anticancer molecular forms of transcriptomic cell lines intrinsic to tumors. Here the rule of greater activity is observed.

EXAMPLE:
for leukemia ***(§FINAL RESULTS/ Leukemia)***:
- basic potential medicines: AACF 1.C., 4.C., 5.C., 5.D., 19, 25, 30, 31.B., 31.C., 34, 39, 40, 45.E, 50, 56.A. and 56.B.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.D., 4.A., 4.B., 5.A., 5.B., 7, 12, 32, 33, 42, 43, 44, 45.B., 49, 50, 51.A. and 51.B..

According to ***Tabl. 7*** it follows that the choice of be:
- basic potential medicines: AACF 40 /in this case the 1st of general activity/;

and ***Tabl. 7*** then:
- duplication of treatment and / or substitution on medical grounds: AACF 1.D. /in this case third in overall activity /.

Table 7 *Substitute pharmaceutical forms for oral use for primary treatment of cancer, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides*

login number*	active pharmaceutical forms for oral use**	UPAC component names⁂
48.		(Z)-2-carbamoyl-4-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)but-2-en-1-yl (E)-3-(4-hydroxyphenyl)acrylate (Z)-2-((((E)-3-(4-hydroxyphenyl)acryloyl)oxy)methyl)-4-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)but-2-enoic acid
55.		2-((S)-2-oxo-3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2,3-dihydrobenzofuran-3-yl)acetamide 2-((S)-2-oxo-3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2,3-dihydrobenzofuran-3-yl)acetic acid

1.D.		(R)-2-phenyl-2-(((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)acetamide (R)-2-phenyl-2-(((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)acetic acid
4.A.		2-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)propanamide 2-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)propanoic acid
4.B.		((2R,3S,4S,5R,6S)-6-((1-amino-2-methyl-1-oxopropan-2-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl 3,4,5-trihydroxybenzoate 2-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((3,4,5-trihydroxybenzoyl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)propanoic acid
32.		(R)-2-(3,4-dimethoxyphenyl)-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)acetamide (R)-2-(3,4-dimethoxyphenyl)-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)acetic acid
42.		2-((2S,4aR,6S,8S,8aR)-8-hydroxy-6-(hydroxymethyl)hexahydro-6H-pyrano[2,3-b][1,4]dioxin-2-yl)acrylamide 2-((2S,4aR,6S,8S,8aR)-8-hydroxy-6-(hydroxymethyl)hexahydro-6H-pyrano[2,3-b][1,4]dioxin-2-yl)acrylic acid
25.		2-(4-(((2S,3R,4S,5S,6R)-6-((((2R,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)phenyl)acetamide 2-(4-(((2S,3R,4S,5S,6R)-6-((((2R,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)phenyl)acetic acid

31.C.		methyl (2S,3R,4S)-4-(((2R,4aR,6S,7R,8R,8aS)-6-((R)-2-amino-1-(3-hydroxy-4-methoxyphenyl)-2-oxoethoxy)-7,8-dihydroxyhexahydropyrano[3,2-d][1,3]dioxin-2-yl)methyl)-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-vinyl-3,4-dihydro-2H-pyran-5-carboxylate (R)-2-(((2R,4aR,6S,7R,8R,8aS)-7,8-dihydroxy-2-(((2S,3R,4S)-5-(methoxycarbonyl)-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-vinyl-3,4-dihydro-2H-pyran-4-yl)methyl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-2-(3-hydroxy-4-methoxyphenyl)acetic acid
46.		(Z)-2-carbamoyl-4-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)but-2-en-1-yl 4-hydroxybenzoate (Z)-2-(((4-hydroxybenzoyl)oxy)methyl)-4-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)but-2-enoic acid

*- sorted by general activity – descending
- this table represents a sample of ***Tabl. 2* and the data from ***§IV.4. 2.*** of ***(Tsanov & Tsanov, 2023)***
***- it is the most active isomeric molecular form. Any kind of optical isomerism is allowed.

If for some reason (financial, logistical, allergic, etc.) the first form cannot be used, then the next molecular form is chosen and so on. The same applies if the activity is too great and this leads to complications in other diseases (including chronic ones for the patient). Then apply (with the same selection) – the substitute per oral pharmaceutical forms in the main treatment of cancer (***Tabl. 7***).

Based on the analysis for determining the medicinal dose of the amide and carboxylic derivatives of amygdalin ***(§IV.1. 3., Tsanov & Tsanov, 2023)***, it follows that the treatment dose for the ratio, **-amide: -carboxylic = 4.87: 1** is:

210-655 *mg PO q6-8hr*; not to exceed 2.3 *g/day*.

!!! If the patient shows allergic symptoms, he should undergo diuretic cleansing, after consultation with a nephrologist - after which the treatment should be started again **!!!**

- synergistic treatment – the very genesis of the treatment we offer is based on chronification of the disease, i.e. its transformation into controlled over time, by means of taking medicinal forms.

That is why there will inevitably come a time when the activity of the preparation will sharply decrease. At this point, the body's clinical response will be directed against the treated substances. That's why we have planned for a certain period of time to replace the medicinal products with those that will

preserve the overall activity. Medicinal substances are divided into two tables for each type of cancer, according to *§**IV.4. 1.*** – conditionally accepted for ***Part 1*** and ***Part 2***. Thus, the clinical doctor can easily select the substitute substances, observing the rule of substitutability according to tables, i.e. if he has chosen a medicinal form from the table. with a ***Part 1*** title, he makes a choice with a ***Part 2*** title (following exactly the same rules).

- Personalized therapy - in a small number of cases, it is necessary to act individually according to the patient's current anamnesis. For this purpose, after the application of the general therapy and / or in combination with it, the specific agent for the respective cell lines must be taken (*§.4.1., Tsanov & Tsanov, 2023*). The ratio of amide to carboxylic acid should again be 4.87:1.

The doctor is only required to comply with the color assessment of activity (activity decreases in order (***§.III.3.4.1.,*** *Tsanov & Tsanov, 2023****)*** - )

- ◊ -

AUTHOR'S NOTES

With the present scientific work we have tried to present in a more generalized form our long-term theoretical research. We tried to draw every value, every dependence and every conclusion precisely, in a form that is not subject to any personal view and/or to be enslaved to a generally "accepted" opinion.

Natural nitrile glycosides would not cross the tumor cell membrane. They decompose to HCN-acid, phenyl methanol and carbohydrate. They do NOT have antitumor activity due to their inability to reach the target unchanged. These compounds, in their natural form, are extremely toxic to the human body. Applying them is not a cure, even at higher concentrations they do more harm than good. Theoretically, we have derived dozens of their modified forms, but their amides and carboxylic acids are the most promising for their introduction in conservative oncology. The fact is that the tumor cell itself is trying to counteract in a way that is quite safe for it.

The knowledge that humanity has gained from the millennial battle between it and tumors, combined with the development of mathematics, statistical and quantum molecular thermodynamics, molecular topology and geometry, clinical oncology, pathophysiology, etc., with the unequivocal contribution of thousands of scientists, we tried to we present this thesis as a sentence and the most modest way to try to confirm and prove it.

- ◊ -

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

HUMAN AND ANIMAL RIGHTS

No Animals/Humans were used for studies that are the basis of this research.

CONSENT FOR PUBLICATION

Not applicable.

AVAILABILITY OF DATA AND MATERIALS

The authors confirm that the data supporting the findings of this study are available within the article.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

REFERENCES

Cadow, J., Born, J., Manica, M., Oskooei, A., & Martínez, M. R. (2020). PaccMann: a web service for interpretable anticancer compound sensitivity prediction. Nucleic Acids Research, 48(W1), W502-8. doi:10.1093/nar/gkaa327

Christopher, A. (2017). Drawing conclusions from data: descriptive statistics, inferential statistics, and hypothesis testing, In Interpreting and using statistics in psychological research. SAGE Publications Inc. doi:10.4135/9781506304144

Dimitrov, S. D., Diderich, R., Sobanski, T., Pavlov, T. S., Chankov, G., Chapkanov, A., . . . Mekenyan, O. (2016). QSAR Toolbox – workflow and major functionalities. SAR and QSAR in Environmental Research, 27(3), 203-19. doi:10.1080/1062936X.2015.1136680

Gary, W. C., Zhengyin, Y., Wensheng, L., & Masucci, A. (2012). The IC50 Concept Revisited. Current Topics in Medicinal Chemistry, 12(11). doi:10.2174/156802612800672844

Ghandi, M., Huang, F. W., & Jané-Valbuena, J. (2019). Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature, 569, 503-8. doi:10.1038/s41586-019-1186-3

Hubert, M., & Vandervieren, E. (2008). An adjusted boxplot for skewed distributions. Computational Statistics & Data Analysis, 52(12), 5186-201. doi:10.1016/j.csda.2007.11.008

Marmolejo-Ramos, F., & Tian, T. (2010). he shifting boxplot. A boxplot based on essential summary statistics around the mean. International Journal of Psychological Research, 3(1), 37-45. doi:10.21500/20112084.823

Sebaugh, J. L. (2011). Guidelines for accurate EC50/IC50 estimation. Pharmaceutical Statistics, 10, 128-34. doi:10.1002/pst.426

Soares, J., Greninger, P., Yang, W., Edelman, E. J., Lightfoot, H., Forbes, S., . . . Garnett, M. (2013). Genomics of Drug Sensitivity in Cancer: a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research, 41(D1), D955-61. doi:10.1093/nar/gks1111

Tsanov, V., Tsanov, H., Theoretical Analysis for the Safe Form and Dosage of Amygdalin Product, Anti-Cancer Agents in Medicinal Chemistry 2020; 20(7), DOI: 10.2174/1871520620666200313163801

Tsanov, V., Tsanov, H., Theoretical Analysis of Anticancer Cellular Effects of Glycoside Amides, Anti-Cancer Agents in Medicinal Chemistry 2022; 22(6), DOI: 10.2174/1871520621666210903122831

Tsanov, V., Tsanov, H., Theoretical Study of the Process of Passage of Glycoside Amides through the Cell Membrane of Cancer Cell, Anti-Cancer Agents in Medicinal Chemistry 2021; 21(12), DOI: 10.2174/1871520620999201103201008

Tsanov, V.; Tsanov, H.,Theoretical study of anticancer activity of glycoside amides [third supplemented edition], pp. 857, ISBN: 978-619-91534-4-4, DOI: 10.5281/zenodo.7295357

Yordanova, D., Schultz, T., Kuseva, C., Tankova, K., Ivanova, H., Dermen, I., . . . Mekenyan, O. (2019). Automated and standardized workflows in the OECD QSAR Toolbox. Computational Toxicology, 10, 89-104. doi:10.1016/j.comtox.2019.01.006

CONTENTS OF FIGURES AND TABLES

Let the preferred version of reading this book be electronic.
Print something really urgent on your recycled paper and printer toner!

This book is constructed in a structure aimed at limiting animal testing in laboratory and preclinical settings.

Only refurbished computers, tablets and smart devices were used in the creation of this book. Good practices have also been applied to reduce energy consumption. The goal is to prevent additional carbon load in the world around us.

Full calculations are posted here*:

Tsanov, V., Tsanov, H. (2023). Interpretable prediction for anticancer sensitivity of glycoside amides (Version 1) [Data set], Zenodo, DOI: 10.5281/zenodo.7550371

*- the information is constantly updated - choose the current version at the moment)

"SAVE TREE" LOGO - HTTPS://WWW.CLIPARTMAX.COM/MIDDLE/M2I8Z5K9K9Z5A0B1_SAVE-TREE-FREE-DOWNLOAD-PNG-SAVE-TREE-LOGO/

"BUNNY – CRUELTY FREE" LOGO - HTTPS://WWW.PNGWING.COM/EN/FREE-PNG-IZVHK

[i] Bibl - King James Version (KJV)